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Chikungunya fever is a non-fatal but highly debilitating disease that affects primates, birds and 
humans. The causative agent is the chikungunya virus (CHIKV), an arbovirus of the Alphavirus 
genus. CHIKV is responsible for the largest epidemic recorded for an Alphavirus, infecting an 
estimated 1.4 to 6 million patients worldwide. Furthermore, it has been recognised by the 
United States army as a potential biological weapon used for bioterrorism owing to the 
potential for infection via aerosol. CHIKV is primarily transmitted by infected Aedes aegypti 
mosquitos and is currently distributed in Africa, parts of Asia and South, Central and North 
America. As a result of the virus genetically adapting to infect the Aedes albopictus mosquito, 
its recent and rapid spread to non-endemic regions has occasioned increasing anxiety as well. 
Infection in humans presents as a sudden onset of fever, rash and severe arthralgia that persists 
for years. At present, there is no fast and effective diagnostic test to distinguish CHIKV from 
other similar viruses. This is a problem because viral infection displays the same symptoms as 
that of dengue, Zika, Ebola and yellow fevers while prognosis, patient care, and persistent 
symptoms of these viruses are very different.  Usually, during the development of a diagnostic 
reagent, Biosafety Level 3 (BSL3) containment is required for purifying antigens from live 
viruses. These lab diagnostic tests are expensive to perform and, in regions facing a CHIKV 
epidemic, are inefficient due to their long waiting periods. This results in patients going 
undiagnosed or misdiagnosed and/or falling outside the window of prophylactic treatment.  As 
such, a cheap and rapid diagnostic reagent to detect the presence of CHIKV antibodies would 
be most advantageous.  
In this study, two recombinant variants of the CHIKV E2 glycoprotein were expressed in 
Nicotiana benthamiana plants to assess their viability for use in a diagnostic reagent for CHIKV 
infection. Two versions of a tobacco sp. codon-optimised, 6xhis-tagged CHIKV E2 envelope 
glycoprotein gene were synthesised and cloned into the plant expression vector, pTRAkc-ERH. 
The E2 glycoprotein is a desirable protein candidate used for a diagnostic reagent as it is a 
major target for neutralizing antibody production against CHIKV during early infection. One 
variant contained a ~52 kDa full length E2 glycoprotein (CHIKV E2-HIS) while the other 
contained a ~49 kDa truncated E2 glycoprotein lacking its transmembrane domain (CHIKV 
E2ΔTM-HIS). Following this, an expression time trial was performed whereby the recombinant 
proteins were expressed in N. benthamiana plants via Agrobacterium-mediated small-scale 
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syringe-infiltration at different optical densities, OD600 = 1.0 and 0.5. To improve expression, 
both genes were co-infiltrated and co-expressed with a human chaperone proteins calreticulin 
(CRT) or calnexin (CNX), or a plant silencing-suppressor protein NSs. Expression of the 
recombinant protein variants alone showed low to undetectable levels of expression in plant 
leaves across 7 days post infiltration (dpi) for both ODs tested. CHIKV E2ΔTM-HIS yielded the 
highest levels of all combinations tested at an OD600 = 1.0 when co-expressed with CRT and 
harvested at 3 dpi.  These parameters were used for subsequent scaling up and production of 
E2 using vacuum infiltration.  
Attempts at purifying CHIKV E2ΔTM-HIS proteins using Ni-NTA affinity chromatography and 
further investigation into the exposure of the 6xHis-tag on the native conformation of CHIKV 
E2ΔTM-HIS indicated that the 6xHis-tag was insufficiently exposed on E2 and thus inaccessible 
to facilitate purification by Ni-NTA affinity chromatography. Further attempts at purifying 
recombinant CHIKV E2ΔTM-HIS proteins by pH purification were also unsuccessful as large 
amounts of plant-protein contaminants present in all samples prevented adequate separation 
from CHIKV E2ΔTM-HIS. A different approach utilising ammonium sulphate precipitation 
facilitated separation of recombinant CHIKV E2ΔTM-HIS from some of the contaminating plant 
proteins in the 30  - 60% ammonium sulphate fraction; however,  large amounts of recombinant 
CRT were co-purified with E2 in this fraction. 
Although expression of a candidate diagnostic reagent in plants for detecting CHIKV antibodies 
in the form of E2 glycoprotein was achieved, further research needs to be done to optimise a 
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Chapter 1: Literature Review  
1.1 Introduction 
Mosquito-borne diseases are responsible for major global health threats. These vectors 
are responsible for the spread of viruses that cause dengue fever, Japanese encephalitis, 
Rift Valley fever, yellow fever, West Nile and Zika, to name a few (Rudolph et al., 2014).  
One other such arbovirus is the chikungunya virus (CHIKV), the causative agent of 
chikungunya fever - a non-fatal but highly debilitating disease that affects primates, birds, 
and humans. The virus was first isolated during an outbreak in 1952 in Tanzania where its 
name originated from, in the native Makonde language, to mean “that which bends 
upward”, describing the contorted posture of patients suffering from the severe 
characteristic joint pain (Schwartz and Albert, 2010). Now, CHIKV is responsible for the 
largest epidemic recorded for an Alphavirus, infecting an estimated 1.4 to 6 million 
patients worldwide (Metz et al., 2013). As an Alphavirus, CHIKV is a spherical, enveloped, 
positive-sense single-stranded RNA virus (Weaver and Lecuit, 2015). Furthermore, CHIKV 
is transmitted by infected female Aedes mosquitos and is currently distributed in Africa, 
parts of Asia and South, Central and North America. Previously, the virus was primarily 
spread by Aedes aegypti mosquitoes (Moulay et al., 2012) found in tropical and 
subtropical regions; however, evidence of a genetic adaptation of the virus to better 
infect Aedes albopictus mosquitos has been credited for the spread of the virus to 
previously non-endemic temperate regions (Tsetsarkin et al., 2007), in addition to the 
rapid and aggressive re-emergence of the virus in countries like India (Mavalankar et al., 
2007). Moreover, CHIKV has been recognised by the United States army as a potential 
biological weapon used in bioterrorism owing to the potential for infection via aerosol 
(Hasan et al., 2018).  Typical infection in humans presents as a sudden onset of fever, rash 
and, its most distinct feature, severe arthralgia that can persist for years (Akahata et al., 
2010).  
While antiviral treatments against CHIKV infection have been studied in animal models 
and in vitro, the effectiveness and safety of these treatments have yet to be determined 
in a clinical setting (Tharmarajah et al., 2017). At present, there is no fast and effective 
diagnostic assay to distinguish CHIKV from other similar co-circulating viruses. This is a 
problem because CHIKV infection displays the same symptoms as that of dengue (Pialoux 
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et al., 2007), Zika (Petersen et al., 2016), Ebola (Rewar and Mirdha, 2014) and yellow 
(Rudolph et al., 2014) fevers while prognosis, patient care, and persistent symptoms of 
these viruses are very different (Prat et al., 2014). While research has gone into 
optimising existing CHIKV diagnostics, they focus primarily on improving the sensitivity 
rather than the time aspect of these assays (Edwards et al., 2007). This is a problem in 
countries like India where approximately 1.4 million cases have been reported since the 
outbreak in 2005 and there exists only two laboratories that can serologically diagnose 
CHIKV (Mavalankar et al., 2007). 
In addition, there is no licensed vaccine available to aid in the prevention and spread of 
CHIKV infection (Pialoux et al., 2007).  While considerable efforts have gone into the 
development of a candidate vaccine against CHIKV – going back as far as the 1960s – 
these vaccine candidates have only been tested in mouse models and most remain in the 
preclinical phase (Burt et al., 2017).  
As such, a rapid and cost-effective diagnostic reagent is desperately needed to detect 
the presence of CHIKV in regions that are challenged with identically-symptomatic 
viruses like dengue fever virus (DENV). Additionally, there is a need for a cost-effective, 
efficacious candidate vaccine against CHIKV that will permit the control of CHIKV 
infection and spread. 
 
1.2 The Chikungunya Virus 
1.2.1 Virus Classification  
CHIKV is an Alphavirus belonging to the Togaviridae family. The Alphavirus genus 
comprises 29 distinct species – those that are threatening to humans typically cause 
severe diseases like encephalitis to milder febrile illnesses accompanied by polyarthritis, 
the characteristic week- to month-long syndrome of CHIKV infection. Furthermore, 
CHIKV belongs to the same genus as Sindbis, Semliki Forest, Ross River, Venezuelan 
equine encephalitis, Barmah Forest, o'nyong-nyong, and Mayaro viruses (Sun et al., 
2019). CHIKV has been listed by the National Institute of Allergy and Infectious Diseases 





1.2.2 Virus Genome and Structure 
CHIKV contains a plus-sense, single-stranded RNA genome approximately 12 kb in length 
(Figure 1.1). Two-thirds of the genome encode four non-structural proteins (nsPs) on the 
5’ end, translated from genomic RNA (Galán-Huerta et al., 2015). These nsPs are 
translated into a polyprotein cassette and subsequently processed into mature nsPs 
involved in viral infection, replication, gene regulation, defence, packaging and protease 
activity (Burt et al., 2017). The remaining third of the genome encodes three structural 
proteins on the 3’ end, translated from subgenomic RNA (Galán-Huerta et al., 2015). Like 
the nsPs, the structural proteins are translated into a polyprotein cassette and 
subsequently processed into mature structural proteins that are essential for virion 
infection and assembly. These proteins include the capsid protein (C) and two surface 
envelope glycoproteins, E1 and E2. The capsid protein is responsible for nucleocapsid 
formation as well as entry to and exit from the nuclei of infected cells (Burt et al., 2017). 
The E1 envelope glycoprotein is responsible for viral entry and the E2 envelope 
glycoprotein is responsible for initiating cell attachment by binding to an unknown 
receptor on the surface of the host cell (Weaver and Lecuit, 2015).  
 
 
Figure 1.1: Organisation of the CHIKV genome. Illustration of the organisation and function of 
the four non-structural and three structural proteins of the CHIKV genome. 26S, 26S ribosomal 
RNA. Reproduced with permission from (Weaver and Lecuit, 2015), Copyright Massachusetts 
Medical Society. 
 
CHIKV is an enveloped virus of ~70 nm with an icosahedral nucleocapsid structure of ~40 
nm encapsidating a single molecule of viral RNA. The viral lipid-bilayer envelope is host-
derived and displays the viral envelope glycoproteins which form 80 trimeric spikes, each 
composed of three E1-E2 heterodimers, on the surface of the virion (Metz et al., 2013) 




Figure 1.2: The typical structure of an Alphavirus virion. The organisation of the structural 
proteins (E1, E2 and CP) and the lipid-bilayer membrane are shown to form heteromeric spikes 
on the surface of the virion. The encapsidated RNA genome is approximately 11.6 kb. Image 
taken from ViralZone: www.expasy.org/viralzone SIB Swiss Institute of Bioinformatics. 
 
1.2.3 Virus Vectors and Transmission 
CHIKV is transmitted by infected female Aedes mosquitos. Usually, the virus circulates in 
a sylvatic cycle between mammalian reservoir or non-human primate hosts; however, it 
has been identified that during urban epidemics CHIKV is transmitted via a human-
mosquito-human transmission cycle . 
The primary carrier of CHIKV is A. aegypti, also called the yellow fever mosquito owing 
to its contribution to the spread of yellow fever virus. With the increase in geographical 
distribution of the mosquito from rural to urban settings, the incidence of CHIKV 
infection has increased. Additionally, increases in travel, insecticide- and drug-resistance 
development, and human activity have contributed to the re-emergence of CHIKV. 
Furthermore, human activity has facilitated the carriage of mosquito eggs over long 
distances. It is thus people, not mosquitoes, that are responsible for the rapid spread of 
A. aegypti as a hatched mosquito does not have a perimeter greater than 200 m (Moulay 
et al., 2012).  
The spread of the virus to previously non-endemic regions has provided evidence that 
CHIKV has genetically adapted to better infect a new mosquito host, Aedes albopictus, 
an inhabitant of temperate regions with a wider geographical distribution (Tsetsarkin et 
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al., 2007). A. albopictus is an aggressive, diurnal and silent vector, rendering prevention 
strategies like bed nets ineffective. It is a resilient species that can thrive in both rural 
and urban environments. Consequently, it has a remarkable capacity to adapt to human 
activity and urbanisation allowing its survival in almost all human-habituated 
environments in dual zoophilic and anthropophilic preferences. Coupled with its 
relatively longer-lived lifespan (4 -8 weeks) and larger flight radius of 400-600m, it has 
superceded A. aegypti in many aspects (Knudsen, 1995). 
 
1.2.4 Geographical Distribution 
CHIKV was first isolated in Tanzania in 1952 and is believed to have originated in Africa. 
Before 2000, CHIKV infection was reported in Angola, Benin, Burundi, Cameroon, the 
Central African Republic, Democratic Republic of the Congo, Gabon, Guinea, Kenya, 
Liberia, Madagascar, Malawi, Nigeria, Uganda, Senegal, Sierra Leone, southern Africa, 
and Sudan. Its subsequent spread to Asia is believed to have occurred via shipping where 
the earliest reports of disease by CHIKV were confirmed in the Philippines in 1954. 
Subsequent outbreaks have been documented in Asia in Bangladesh, Bhutan, Cambodia, 
China, India, Indonesia, Laos, Malaysia, Maldives, Burma/Myanmar, Pakistan, Saudi 
Arabia, Singapore, Sri Lanka, Taiwan, Thailand, Timor, Vietnam, and Yemen (Burt et al., 
2017). After disappearing for more than a decade, the virus re-emerged through 
dissemination by A. albopictus causing outbreaks of higher severity in the same areas 
and areas previously not affected by CHIKV. For example, several outbreaks were 
reported after the re-emergence of CHIKV in new geographical areas such as Europe (UK, 
Belgium, Germany, Czech Republic, Norway, Spain and France), Hong Kong, Canada, 
Taiwan, Sri Lanka, and the USA (Powers and Logue, 2007). Figure 1.3 represents the 





Figure 1.3: The geographical distribution of the Aedes mosquito and respective CHIKV strains. 
Coloured symbols indicate reported autochthonous CHIKV cases with a colour overlay indicating 
the geographical range of the two primary vectors responsible for mosquito-human-mosquito 
transmission of CHIKV. ESCA = East/South/Central African. Reproduced with permission from 
(Silva and Dermody, 2017), Copyright American Society for Clinical Investigation.  
 
Most dramatically, in 2005, the Indian government reported more than 1.4 million cases 
of CHIKV infection in 12 states in the country. This was an underestimate because no 
surveillance system existed for CHIKV until 2006 (Mavalankar et al., 2007).  It is estimated 
that nearly 40% of the world’s population is at risk of CHIKV infection as outbreaks 
continue to occur globally (Wimalasiri-Yapa et al., 2019). 
 
1.2.5 Clinical Symptoms  
Infection by CHIKV is accompanied by a range of signs and symptoms of variable 
intensities in patients, with only 5 – 15% of infections being asymptomatic (Appassakij et 
al., 2013). Acute infection is most commonly characterised by the sudden onset of severe 
joint and muscle pain, a maculopapular rash ranging from a mild, localised rash to one 
more widespread (some covering 90% of the body), a fever higher than 39 oC (Miner et 
al., 2015), headache, lethargy (Weaver and Lecuit, 2015) and back pain. These symptoms 
usually resolve within two weeks; however, arthralgia may persist for months or even 
years (Galán-Huerta et al., 2015). While death from CHIKV infection is rare (1-in-1000 
patients), cases of encephalitis, encephalopathy, myocarditis, hepatitis and multi-organ 
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failure have been reported in severe infections. Additionally, infected neonates, people 
above the age of 65 years and immunosuppressed patients are at an increased risk of 
severe infection (Burt et al., 2017).  
Throughout history, these febrile symptoms were often mistaken for infection with 
o’nyong-nyong virus, Sindbis virus or DENV, the fastest spreading mosquito-borne virus 
in the world. However, the incapacitating arthralgia is what discerns CHIKV from DENV 
specifically (Carey, 1971). While CHIKV and DENV are two of the most difficult infections 
to distinguish between, symptoms of CHIKV infection are more abruptly onset. Rash and 
arthralgia are also more frequent in CHIKV than DENV infection (Pialoux et al., 2007).  
 
1.3 Envelope Glycoproteins 
The CHIKV envelope glycoproteins, E1 and E2, form part of the structural polyprotein 
cassette translated from a 26S subgenomic mRNA and are further proteolytically 
processed into the viral envelope glycoproteins. The 80 trimeric spikes formed by 
multiple E1-E2 heterodimers are essential for the budding of new virus particles. Cell 
entry via pH-dependent endocytosis is facilitated by E1, while recognition and 
attachment of unknown host receptors is facilitated by E2. The envelope polyprotein 
cassette (E3-E2-6K-E1) (Figure 1.1) is processed in the endoplasmic reticulum and the 
resulting E1 and membrane-bound precursor E2 (E3-E2) form heterodimers that 
trimerise to form the trimeric spikes. Finally, precursor E2 undergoes furin-dependent 
cleavage, releasing E3 to form mature trimeric spikes which are displayed on the surface 
of the virion (Metz et al., 2013).  
CHIKV E1, a class II fusion glycoprotein, mediates viral membrane fusion with a cell 
membrane, as a trimer, via a low pH-dependent insertion and subsequent refolding to 
form a hairpin-like structure. The recently emerged CHIKV mutant (bearing an E1-A226V 
substitution), has been found to have allowed the virus to adapt to the broader-
distributed host, A. albopictus. It is estimated that the E1 glycoprotein may have a lower 
chance of exposure to a host’s immune system due to the envelope protein being more 
buried within the structure of the virions (Kuo, Chen et al. 2012). Therefore, CHIKV E1 is 
not an ideal candidate for use in the development of a diagnostic assay. 
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CHIKV E2, a type I transmembrane glycoprotein, mediates receptor binding during the 
Alphavirus lifecycle (Cho et al., 2008). A study by Kuo et al. (2012) showed that the E2 
glycoprotein in alphaviruses both facilitates CHIKV E1 glycoprotein folding and regulates 
E1 fusogenicity. Like E1, there is evidence to suggest that the E2 glycoprotein underwent 
a mutation event that facilitated the adaptation of CHIKV to the more successful A. 
albopictus vector. It is suggested that the mutation enhanced CHIKV infectivity in the 
mosquito midgut possibly via the fusion step in the endosome (Matusali et al., 2019). In 
addition, the CHIKV E2 glycoprotein is a major target for neutralizing antibodies against 
CHIKV (Fox et al., 2015) during early infection owing to an epitope located on the N-
terminus of the glycoprotein. As a result, the E2 glycoprotein is an appropriate protein 
candidate for use in the development of a diagnostic assay for early detection of CHIKV 
infection in sufferers (Kam et al., 2012). 
CHIKV E1 and E2 are predicted to be glycosylated at N141, and N263 and N273, 
respectively (Metz et al., 2011). Asparagine (N)-linked glycosylation is an important co- 
and post-translational modification that these envelope proteins must undergo when 
entering the secretory pathway. In addition, N-glycans are crucial for protein folding, 
stability and modulating protein-protein interactions. Many human therapeutics derived 
from recombinant biopharmaceuticals are N-glycosylated; as such, N-glycosylation is 
important for recombinant glycoprotein production as it influences their heterogeneity 
and affects the biological function of these products. Furthermore, incomplete N-
glycosylation may give rise to recombinant proteins with unwanted characteristics. 
Recombinant glycoprotein glycosylation in mammalian cells is typically efficient, whereas 
glycosylation in plants, insect cells and other expression systems, such as Pichia pastoris, 
display differences in glycosylation compared to mammalian cells (e.g. plants harbour a 
β(1,2)-xylose glycan core whereas mammals do not and the α(1,6)-fucose in mammals is 
substituted by an α(1,3)-fucose in plants) – this may alter the above mentioned protein 
folding, stability and modulation of protein-protein interactions with unknown effects 
thus affecting the efficiency of glycosylation in these alternative, non-natural host 
systems. To remedy this, in a Nicotiana benthamiana expression system Castilho et al. 
(2018) co-expressed immunoglobulins and other recombinant human glycoproteins 
(erythropoietin, interferon-ɤ and the Fc antibody region) with a recombinant 
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oligosaccharyltransferase from Leishmania major. The results showed a significant 
increase in N-glycosylation efficiency for some proteins and a promising tool for 
producing recombinant glycoprotein therapeutics in N. benthamiana.   
 
1.4 CHIKV Therapeutics, Diagnostics and Vaccines 
While the mortality rate of CHIKV infection is relatively low, the debilitating nature of the 
disease and its corresponding economic burden is such that the development of 
therapeutics, diagnostic assays and candidate vaccines against CHIKV are important 
considerations for combating CHIKV spread and infection, effectively diagnosing possible 
sufferers early in high risk-areas and limiting the burden of the disease (Silva and 
Dermody, 2017).  
 
1.4.1 Current Therapeutics 
At present, there are no licensed anti-CHIKV therapeutics available; however, numerous 
therapeutic strategies have been investigated. Certain antivirals, for example, have been 
discovered or developed to directly target the CHIKV replication cycle thereby inhibiting 
viral entry, replication and/or viral release (Tharmarajah et al., 2017). Pre-existing 
antivirals have been tested for anti-CHIKV properties and it was found that ribavirin in 
combination with interferon-alpha (IFN-α), used in CHIKV-infected patients, showed 
positive anti-CHIKV effects in vitro – it is the only FDA-approved drug in humans that 
produced this response (Turner et al., 2014). Similarly, favipiravir (T-705), an anti-
influenza virus agent, in combination with its defluorinated analogue T-1105 inhibited 
CHIKV replication in vitro (Delang et al., 2014). Likewise, harringtonine, a plant alkaloid 
compound used to treat chronic myeloid leukaemia, mycophenolic acid, an 
immunosuppressant used for organ transplantations (Kaur et al., 2013), and 6-
azauridine, an anti-metabolite (Pohjala et al., 2011), displayed CHIKV replication 
impairment in vitro. Additional small-molecule antivirals such as nucleoside analogue β-
D-N4-hydroxycitidine (NHC) have been shown to inhibit CHIKV replication in vitro 
(Ehteshami et al., 2017) and proved to be more potent than ribavirin and favipiravir 
(Tharmarajah et al., 2017). 
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Monoclonal antibodies as therapeutics or prophylactics against CHIKV have also been 
investigated since a humoral response and neutralizing antibodies against CHIKV clades 
and other alphaviruses are often protective strategies. In mice, passive immunisation by 
transfer of antisera or isolated monoclonal antibodies has been shown to be protective 
against CHIKV (Selvarajah et al., 2013). In addition, monoclonal antibodies as a 
postexposure therapeutic, even when administered in the late stages of infection, have 
been shown to be protective in mice against CHIKV (Fric et al., 2013). These showed 
further promise for the use of immunotherapy as a therapeutic against CHIKV disease.  
Although the discovery of these antiviral and therapeutic compounds has shown 
protective promise against CHIKV infection, further studies in animal and human trials 
are needed for the advancement of these drugs. The best strategy against CHIKV 
infection and spread is likely to be an effective vaccine (Silva and Dermody, 2017).   
 
1.4.2 Current Diagnostic Assays 
The overlapping symptoms, geographical distribution and, in some cases, vectors shared 
by CHIKV, DENV, o’nyong-nyong, Mayorovirus and other similarly-symptomatic viruses 
highlight the need for definitive diagnostics to unambiguously identify CHIKV infection. 
An effective diagnostic will permit early detection of infection and, consequently, an 
appropriate clinical and public health response (Pezzi et al., 2019).  
To date, three common laboratory assays are used to diagnose CHIKV infection: virus 
isolation, serological testing and reverse transcriptase-polymerase chain reaction (RT-
PCR) (Galán-Huerta et al., 2015). While virus isolation is the most definitive diagnostic 
strategy, it is not a strategy that fits the need for early diagnosis of CHIKV infection. Virus 
isolation is being replaced with faster, more sensitive and safer molecular techniques 
that do not require the laboratory infrastructure needed for virus isolation.  However, 
virus isolation should not be discounted for the fact that it can accurately characterise 
circulating strains and can further assist with the development of future diagnostic assays 
(Pezzi et al., 2019). A limitation of this method is that the blood sample needs to be 
transported between 2 – 8oC and used within 48 hours.  
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For serological assays, sera from whole blood, obtained from acute and recovering 
sufferers, can be used in enzyme-linked immunosorbent assays (ELISA). Like virus 
isolation, the non-frozen specimen needs to be transported at 2-8°C. These assays rely 
on CHIKV-specific IgM levels and a four-fold rise in IgG titre for diagnosis (Galán-Huerta 
et al., 2015). Unfortunately, samples collected during the acute and convalescent stages 
of the disease are used for a reliable diagnosis of CHIKV infection. As such, this technique 
is not ideal for early reliable diagnosis of infection.  
RT-PCR is the more frequently used technique for diagnosis and the use of serum from 
whole blood is favoured. Other clinical samples like urine, saliva, semen, cerebrospinal 
fluid, and breast milk have been used; however, the time window for some samples (i.e. 
breast milk and urine) remain unclear and are often contradictory in the literature 
(Grivard et al., 2007, Campos et al., 2017). Issues with this strategy of diagnosis arise 
when mismatches occur between different strains of the virus and in-house primers 
(published in the literature) are used. In addition, for commercial real-time PCR assays, 
very limited or no information is available regarding the adequacy of the lineages of the 
CHIKV strains detected and how these kits were evaluated (Pezzi et al., 2019).  
While these tests are reliable and sensitive, they require regularly maintained and 
sophisticated infrastructure and medium-to-high level skilled technicians to operate. 
These requirements may not be available for certain laboratories, especially in rural areas 
and areas lacking sophisticated infrastructure where outbreaks typically occur. As such, 
a reliable capture antigen-based rapid diagnostic assay has been recommended for the 
control of outbreaks and discrimination between co-circulating febrile viruses (Burdino 
et al., 2016). A recently developed capture antigen-based diagnostic assay used a 
recombinant CHIKV E2 capture antigen produced in E. coli. While the developed assay 
was simple, specific and sensitive, it was produced in a relatively expensive expression 
system (Fumagalli et al., 2018). Recombinant CHIKV E1 and E2 envelope glycoproteins 
have also been expressed in Sf9 cells (insect cell line) using a baculovirus vector-based 
approach. Their seroreactivities were evaluated by indirect IgM-capture ELISA. 
Recombinant CHIKV E1 showed a sensitivity of 77.5% while recombinant CHIKV E2 
showed a sensitivity of 90% (Cho et al., 2008). However, these recombinant antigens 




1.4.3 Current Vaccine Candidates 
While there is no commercialised vaccine against CHIKV, various vaccine strategies have 
been investigated, allowing for some candidates to advance to preclinical and clinical 
studies. Summarised here are the candidates that have advanced to human studies.  
TSI-GSD-218 is the first reported live-attenuated candidate vaccine against CHIKV. 
Attenuation of CHIKV is credited to a two-point mutation (T12I and G82R) of the E2 
glycoprotein. The candidate vaccine displayed immunogenicity in mice and non-human 
primates (NHPs) and conferred protection in NHPs when challenged with CHIKV (Levitt 
et al., 1986). TSI-GSD-218 showed no adverse effects in phase I clinical trials and was 
highly immunogenic in phase II clinical trials with a single immunisation; however, 
approximately 8% of the subjects displayed transient febrile symptoms. Furthermore, as 
residue 82 is the dominant attenuating factor and influences CHIKV-specific neutralizing 
antibody production, observing reversion at this residue in mice and humans raised 
concerns about attenuation stability and the resulting safety of the vaccine.  
Consequently, the candidate vaccine was ceased after phase II studies (Edelman et al., 
2000). 
Another vaccine candidate, CHIKV/IRES, contains an encephalomyocarditis virus internal 
ribosomal entry site (IRES) sequence in place of the subgenomic promoter which serves 
to limit the expression of viral structural proteins. This modification allows for the 
attenuation of viral replication in mammalian cells and prevents replication in insect cells, 
thereby inhibiting replication in mosquito cells. Furthermore, the CHIKV/IRES vaccine 
candidate is safe, it displayed high immunogenicity in mice and NHPs, and remained 
attenuated (Plante et al., 2015).  
Other such promising strategies are those of virus-like particle (VLP)-based vaccine 
candidates. CHIKV VLPs are made by expressing the structural polyprotein cassette via a 
DNA-expression plasmid transformed or transfected into an expression platform. The 
resultant particles mimic intact virions, however, due to a lack of genomic viral RNA, they 
are replication-incompetent.  VRC-CHKVLP059-00-VP, a VLP-based candidate, is derived 
from DNA-transfected human embryonic kidney (HEK) cells. While it has been shown to 
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be safe, highly immunogenic and cross-protective against multiple CHIKV strains in mice 
and NHPs, multiple doses are required, and manufacturing costs are high (Akahata et al., 
2010, Plante et al., 2015). VRC-CHKVLP059-00-VP is in phase II trials. Another VLP-based 
candidate vaccine in phase II trials makes use of a recombinant, live-attenuated measles 
virus (MV) vector (MV-CHIKV). The vaccine candidate was well tolerated and protective 
against lethal challenge due to its cross-neutralising immune response; however, 
multiple doses were required for 100% seroconversion and 58% of the high-dose cohort 
displayed adverse effects to multiple vaccinations (Ramsauer et al., 2015).  
Other approaches have included other live-attenuated strategies including viral gene 
deletions, glycosaminoglycan binding modifications, alphavirus chimaeras, and codon 
alterations, as well as strategies that have included inactivated particles, subunit, and 
DNA- and recombinant virus-vectored vaccines (Silva and Dermody, 2017). 
Even with the promise of CHIKV treatments and diagnostics, the most effective 
eradication and control strategy for CHIKV infection is still prevention via an efficacious 
vaccine.  Despite the potential of these vaccine candidates, there are still numerous 
obstacles that need to be overcome. The ideal vaccine candidate must illicit a robust 
immune response, be cost-effective and ideally be administered in a single dose. This 
introduces the challenge of balancing vaccine safety and immunogenicity while 
maintaining economic viability regarding vaccine production and licensing (Silva and 
Dermody, 2017). 
 
1.5 Plant-Based Protein Expression and Downstream Processing (DSP) 
1.5.1 Expression in Plants 
Until recently, mammalian cell lines such as Chinese Hamster Ovary (CHO), yeast and 
bacterial cell lines were predominantly used for biopharmaceutical production. With the 
current rise in demand for biopharmaceuticals, alternatives to mainstream expression 
systems that are cheaper, safer and more convenient are being investigated. Plants are 
one such attractive alternative that have emerged as a result of their high scalability, low 
capital and production costs, minor differences in glycosylation compared to traditional 
expression systems, and safety owing to their lack of oncogenic DNA sequences and 
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prions (Tschofen et al., 2016, Rybicki, 2017). However, there are some factors to consider 
pertaining expression yields in plant expression technologies. 
While plant expression systems are impressive alternatives, they were not without their 
issues in their early years and, in some respects, even now. Since, many technical 
advances have been achieved to relieve the technology of these issues and further 
shuttle plant-based expression into the affordable technology that it is now (Fischer et 
al., 2004). One key problem was/is low expression yields. While it is rare for plant-based 
based system to reach the protein yields of traditional expression system, protein yield 
in plants can be further optimised by controlling genetic and epigenetic factors, in 
addition to cultivation parameters (Schillberg et al., 2019). Factors that determine 
expression yield include: the host species, gene silencing, transcription and translation 
efficiency, promoter activity and specificity, codon usage, subcellular targeting and the 
corresponding stability of the produced recombinant protein, and the expression 
system/construct. These factors should all be considered during upstream study design. 
A range of plant species have been used in molecular farming: leafy crops, cereals, fruit 
and vegetable crops, and some miscellaneous species. Tobacco has the highest biomass 
of the crop species used, it is easily and highly scalable, fully optimised for gene transfer 
and expression and, owing to its non-food, non-crop status, it has a lower risk of food or 
feed chain contamination (Ma et al., 2003). Transcription efficiency can be optimised 
using an effective promoter, like the strong constitutive promoter of the Cauliflower 
mosaic virus (CaMV), 35S (Fischer et al., 2004), and a polyadenylation signal, like the 
Agrobacterium tumefaciens nos gene . Translation efficiency can be optimised by 
adapting, and thus optimising, codon usage to that of the host species (Liénard et al., 
2007). Subcellular targeting of proteins also affects protein stability. This is because the 
compartment in which the protein accumulates influences its assembly, folding and post-
translational modifications. The secretory pathway has been shown to result in better 
assembly and folding of glycoproteins, for example, than the cytosol. This must be 
considered during construct design by the addition of a compartment-specific C- or N-
terminal signal-peptide sequence in the expression construct. Previous optimisation of 
these factors has allowed for cheaper upstream costs of plant-produced biologics in 
contrast to itself (in the early years of the technology) and other traditional expression 
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systems (mammalian/insect cell lines and microbial fermentation). Like upstream 
processing, there is much to be considered for downstream processing of recombinant 
plant-produced proteins (Nagels et al., 2012).  
 
1.5.2 Downstream Processing of Recombinant Proteins 
Downstream processing of plant-derived recombinant proteins accounts for the majority 
of the production costs in extraction, purification and characterisation (Nandi et al., 
2016). Hence, reducing upstream costs is one of the fundamental advantages of plant-
expression systems. It has become clear that different expression hosts come with their 
own set of advantages and disadvantages regarding DSP. As a result, DSP infrastructure 
availability and extraction/purification protocols should be considered. 
Purification costs can be reduced using affinity tags (e.g. polyhistidine tag) on one or both 
termini of the protein. A disadvantage that may arise by the addition of a tag/tags is their 
interference on the activity and/or structure of the protein. Thus, the possibility of 
removing the tag(s) from purified recombinant proteins may be necessary for the 
restoration of the activity and/or structure of the protein (Fischer et al., 2004).  The 
addition of an affinity tag, the polyhistidine tag specifically, allows for relatively 
inexpensive, large-scale one-step purification procedures through metal affinity 
chromatography. This method uses adsorbents that are resistant to chemical and/or 
biological degradation and boast a high protein-binding capacity. Another efficient 
method is ion-exchange chromatography. Both of these methods can be used on a 
variety of biomolecules. (Platis et al., 2008).  
 
1.5.3 Transient Expression in Tobacco  
The value of molecular farming, as an alternative to traditional production platforms like 
E. coli and mammalian cells, is such that large amounts of pharmaceutically important 
proteins can be produced in more affordable ways. Proteins can be expressed in 
transgenic or transient systems. Each method of expression has its respective advantages 
and disadvantages (Fischer and Emans, 2000).  
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With the emergence of transient expression, the process of expression has significantly 
sped up compared to transgenic expression as screening of the recombinant protein of 
interest and large-scale production are possible within days (Castilho et al., 2018). There 
are three major methods of transient-expression: delivering a gene into plant cells by 
particle bombardment, Agrobacterium-mediated gene transfer and the use of modified 
viral vectors. Agrobacterium-mediated gene transfer delivers DNA to more cells than 
particle bombardment that not only reaches fewer cells, but is also not ideal for large-
scale expression and, the DNA also needs to reach the nucleus for DNA transcription 
(Christou, 1996). In addition, the T-DNA containing the gene of interest is actively 
delivered to the nucleus when using agroinfiltration. This method can produce suitable 
amounts of protein when scaled up which may be sufficient for pre-clinical trials thus 
bypassing the need for a stable-expression plant line. Viral vectors deliver the gene of 
interest to most cells and transcription of this gene is achieved by viral replication in the 
cytoplasm which transiently delivers many transcripts of the gene of interest (Fischer and 
Emans, 2000). Viral vectors offer the advantage of autonomous replication, and their 
characteristic high levels of multiplication and naturally occurring transient expression 
levels. Viral vectors operate through transient RNA and DNA replicons that are viral-
based and offer the rapid advantage of high levels of expression; however, the lack of 
stability of the foreign gene in the viral genome may pose problems (Scholthof et al., 
1996).  
 
1.6 Plant-Based Research for CHIKV 
Worldwide, developing countries are the most affected by CHIKV epidemics. To combat 
this, plant-based expression platforms have been proposed as the tool to address the lack 
of vaccine and rapid diagnostic kit development and availability. In addition to its 
scalability, safety, efficiency and product quality, it operates at a fraction of the cost (0.1 
to 10%) of traditional expression platforms like bacteria and mammalian cell-culture 
(Cardona-Ospina et al., 2016).  
Beforehand, protein candidates that may potentially be used for the development of a 
biopharmaceutical should be defined. For a diagnostic assay: these proteins should be 
highly conserved (Cardona-Ospina et al., 2016). As per previous research done on CHIKV, 
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CHIKV nsP1 cysteine protease has high genetic diversity and is unsuitable for use in a 
diagnostic assay. Likewise, the other non-structural proteins are not suitable for use in a 
diagnostic assay. (Bao et al., 2013). The CHIKV envelope glycoproteins E1 and E2 are each 
suitable for the development of a rapid diagnostic kit. Both glycoproteins are highly 
conserved; however, plant glycosylation of these recombinant proteins may modify their 
effectiveness (Khan et al., 2012, Weber et al., 2015). The CHIKV E2 protein is the most 
conserved protein of the structural protein cassette and is responsible for earliest 
elicitation of an antibody response (Kam et al., 2012).  
In addition, the plant system for the expression of recombinant CHIKV proteins should be 
chosen based on availability of infrastructure, risk of contamination, the effects of 
secondary metabolites on DSP, and the previous success of transformation protocols on 
certain plant species e.g. Agrobacterium-mediated infiltration is particularly effective for 
transformation of Nicotiana benthamiana, N. tabacum and Solanum tuberosum. The 
transient method of agroinfiltration is preferred as it can provide suitable yields of protein 
short term (Cardona-Ospina et al., 2016).  
 
1.7 Project Aims and Objectives 
The development of a rapid diagnostic assay to screen for CHIKV antibodies in sera is 
currently expensive and hazardous owing to the BSL conditions required for the operation 
of live virus-infected tissue and its products. The aim of this study was to develop a CHIKV 
diagnostic reagent by expressing recombinant variants of the CHIKV E2 glycoprotein, 
using a tobacco plant-based transient-expression system. The following encompasses the 
approach used: 
 Synthesis of two codon-optimised CHIKV E2 glycoprotein gene variants and cloning into 
two plant expression vectors, pEAQ-HT and pTRAkc-ERH, in E. coli. 
 Transformation of appropriate Agrobacterium tumefaciens strains with recombinant 
plant expression constructs.  
 Agrobacterium-mediated infiltration of N. benthamiana leaves with different plant 
expression constructs. This includes co-infiltration with recombinant human chaperone 
proteins and an RNA-silencing suppressor protein to determine which combination, if 
any, provides optimal CHIKV E2 glycoprotein expression.  
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 Screening of plant produced CHIKV E2 glycoprotein variants to determine which day post-
infiltration the recombinant proteins are expressed the highest.  
 Selection of plant expression construct and conditions for large-scale expression and 


























Chapter 2: Expression of Recombinant CHIKV E2 Glycoprotein Variants in 
Plants 
2.1 Introduction  
In this chapter, the small-scale transient expression of the two CHIKV E2 glycoprotein 
variants in tobacco plants is described and analysed to select the best-expressed variant 
and its conditions for analysis in large scale expression. The CHIKV envelope 2 (E2) 
glycoprotein has been shown to be potently immunogenic owing to a single linear 
epitope located on the N-terminus of the glycoprotein. This epitope protrudes from the 
virion and is the major target of detection by antibodies during the early phase of 
infection. This protein is therefore an appropriate target for use as a reagent in an assay 
for the diagnosis of relatively undiagnosed/misdiagnosed CHIKV (Kam et al., 2012). Two 
recombinant variants of the CHIKV E2 glycoprotein have previously been expressed in 
insect cells at high levels (Metz et al., 2011); however, the variant lacking the C-terminal 
transmembrane domain showed higher levels of expression than the full-length CHIKV 
E2 glycoprotein  In addition, it has been seen that expression of general transmembrane-
containing proteins utilising the plant-expression planform elicits necrotic symptoms on 
the leaves of tobacco-plant hosts (Peyret and Lomonossoff, 2013). These symptoms have 
been shown to alleviate upon expression of the same, transmembrane domain-deficient 
protein. This truncation also improved expression and purification of the protein. These 
more favourable aspects suggest that it is worth investigating the expression of 
recombinant transmembrane-containing and transmembrane-deficient CHIKV E2 
glycoprotein variants in the more cost-effective, rapid and highly scalable plant-
expression system.  
During the design of a cloning strategy for recombinant protein expression in plants, 
there are many tools that can be implemented to assist with optimisation of gene 
expression, protein folding, protein detection and protein purification. Optimisation of 
these processes help with the time and cost aspects of the research and end product 
integrity. Codon optimisation of recombinant gene sequences is one important tool as 
codon usage, while seemingly random, varies between organisms (Stratford et al., 2000). 
The expression of an exogenous gene may be impeded as a result of the protein coding 
regions of the exogenous gene having a codon usage pattern different to that of the host 
organisms. Codon optimisation may improve the translation efficiency of exogenous 
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genes as it rhymes the protein coding usage of the coding regions (Fuglsang, 2003). 
Previous research on expressing a recombinant plant-produced human epidermal 
growth factor (hEGF), a powerful mitogen being recombinantly produced on a 
pharmaceutical scale that enhances the healing of a wide range of injuries, showed that 
optimising the recombinant gene’s codons for plant expression increased hEGF yield by 
~34% (Thomas and Walmsley, 2014). Similarly, the expression of a plant codon-optimised 
tetanus toxin’s non-toxic fragment C (TetC), for the development of a subunit vaccine 
against tetanus in tobacco plants, accumulated to be 10% of the total soluble proteins 
(TSP) extracted from harvested leaf material (Tregoning et al., 2003). For the expression 
of a protein to become economically viable, it should preferably accumulate to at least 
1% of TSP (Rybicki, 2009). 
Furthermore, to assist with protein targeting to the endoplasmic reticulum (ER), where 
they will undergo the process of proper folding, a signal-peptide sequence can be fused 
to recombinant gene sequences. One such signal peptide is the Leader Peptide Heavy 
(LPH)-signal peptide derived from the murine monoclonal antibody mAb24 heavy-chain 
gene used to target recombinant proteins to the secretory pathway (Schillberg et al., 
1999). Previous fusion of the LPH-signal peptide onto a recombinant N. benthamiana 
plant-produced Rift Valley fever virus (RVFV) Gn glycoprotein, chimeric RVFV 
Gn/influenza HA particle-forming fusion protein (Mbewana, 2017), and  HIV Env gp140 
protein (Margolin et al., 2019) has shown promise for the production of these proteins 
as a result of the signal peptide’s targeting function.  
An advantage of using tobacco plants as a transient expression system is that it allows 
for rapid production of proteins which can then be screened through antibody-related 
assays like western blotting and enzyme-linked immunosorbent assays (ELISA); however, 
detection of these plant-produced proteins is dependent on the availability and 
specificity of commercialised/in-house antibodies which are often lacking and not very 
specific. In order to bypass this problem, recombinant proteins can be fused to an 
assortment of affinity tags for which commercial antibodies are commonly available. This 
bypasses the requirement for  protein-specific antibodies  and allows for efficient 
downstream one-step purification of the recombinant tagged protein through the tag’s 
ability to bind to certain resins (Einhauer and Jungbauer, 2001). One such affinity tag is 
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the calmodulin-binding protein (CBP). CBP is a 26 amino-acid peptide obtained from the 
muscle myosin light chain kinase (MLCK) which binds to calmodulin with relatively high 
affinity (Zheng et al., 1997); however, the affinity resin is relatively expensive (Waugh, 
2005). Another useful affinity tag is glutathione S-transferase (GST), a 218 amino-acid 
peptide that offers the advantage of potential protein solubility (Sehr et al., 2001) and 
inexpensive GSH-Sepharose affinity resin; however, large protein tags often burden the 
expression host metabolically (Waugh, 2005).  
The smaller and  highly-specific 8-amino acid FLAG™ marker peptide is very effective but  
scale-up procedures are costly as a result of the tag’s low binding capacity and expensive 
resin (Einhauer and Jungbauer, 2001). One of the most popular affinity tags is the 
polyhistidine tag (6xHis-tag), which comprises six neighbouring histidine residues fused 
to either the N- and/or C-terminus of the recombinant protein. Additionally, the tag can 
be removed by engineering a cleavage site between the N- and/or C-terminus of the 
protein of interest and the fused 6xHis-tag (Zentgraf et al., 1995) and primary antibodies 
are commercially available for immunoassay detection. Thus, the fusion of a 6xHis-tag 
onto recombinant gene sequences during cloning is often beneficial to the costs and 
efficiency involved with downstream protein detection and purification. One significant 
disadvantage of using the 6xHis-tag is that the detection antibody can be promiscuous. 
This has the potential to result in background detection of proteins that are not the 
protein of interest (Kimple et al., 2013).  
Although some proteins are expressed at high levels in plants, glycoproteins in particular 
seem to be expressed at very low levels. Evidence suggests this can be credited to the 
inherent differences in endogenous chaperone machinery between the plant and natural 
mammalian cell hosts - where viral glycoproteins are naturally produced - in addition to 
a potential bottleneck in the plant folding machinery to produce exogenous viral 
glycoproteins (Margolin et al., 2018). Furthermore, it has been shown that the expression 
of viral glyco-antigens produces a pathology in the plants indicative of plant ER-stress 
(Pera et al., 2015, Phoolcharoen et al., 2011). Chaperone proteins are responsible for the 
correct folding, during or after synthesis, of proteins.  Two chaperones that have 
previously been shown to improve expression of recombinant proteins in plants, when 
co-expressed with the protein of interest, are human chaperones calreticulin (CRT) and 
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calnexin (CNX). Membrane-bound CNX and soluble CRT are both quality-control proteins 
that recognise glycoproteins, facilitate their folding in the ER and prevent incompletely 
or misfolded proteins from exiting the ER (Nagels et al., 2012). Previous work on 
improving recombinant protein production by co-infiltration of N. benthamiana plants 
with chaperones showed an increase in yields of E. coli type-3 secretion system proteins 
when co-expressed with the chloroplast-targeted chaperone CesT (MacDonald et al., 
2017).   
Another helper protein that may improve recombinant protein expression yields in 
plants is the RNA-silencing suppressor NSs protein from the tomato spotted wilt virus 
(TSWV). Plants harbour a post-transcriptional RNA silencing defence system that 
recognises and degrades transgenes from invading pathogens. The NSs protein encoded 
by the TSWV supresses this innate RNA silencing activity of plants (Takeda et al., 2002); 
as such, it can be used as a tool to suppress the deleterious effects of RNA silencing of 
exogenous expression of recombinant proteins and improve their expression. 
In this study, two codon-optimised gene variants of a recombinant CHIKV E2 glycoprotein 
were designed to be expressed in a N. benthamiana transient-expression system. The 
6xHis-tag was fused to the C-terminus of each gene variant for efficient downstream 
detection and purification purposes. The glycoprotein gene variants were cloned into 
transient plant expression vectors, pTRAkc-ERH (Meyers et al., 2008) and pEAQ-HT 
(Sainsbury et al., 2009). pTRAkc-ERH contains an LPH signal-peptide sequence on the 5’ 
of the multiple cloning site (MCS) which is consequently fused onto the 5’ terminus of 
the gene inserts during cloning; the pEAQ-HT vector does not contain this signal-peptide 
sequence. These constructs were transformed into Agrobacterium tumefaciens and 
infiltrated into N. benthamiana leaves using Agrobacterium-mediated infiltration.  They 
were infiltrated either individually or co-infiltrated together with Agrobacterium strains 
harbouring the human chaperones calreticulin or calnexin or the RNA-silencing 
suppressor NSs.  Samples were harvested at various days post infiltration to determine 





2.2 Materials and Methods 
2.2.1 Gene Design and Synthesis 
A DNA consensus sequence (Appendix, Fig. A1) of three South African CHIKV isolates 
(GenBank: HM045792.1, Vereeniging, Gauteng province; HM045795.1, SAH2123 strain; 
HM045805.1, CHIKV AR 18211 1976) was used to design two gene variants of the CHIKV 
E2 glycoprotein (Ann Meyers, Biopharming Research Unit). Information on the South 
African isolates were gathered from Volk et al. (2010). One gene variant contained the 
full length E2 glycoprotein sequence including the transmembrane domain (TMD), and 
the other gene variant lacked the TMD (ΔTM). These were Nicotiana sp. codon-optimised 
using the OptimumGeneTM algorithm, synthesised and supplied in a pUC57 vector using 
the EcoRV blunt-end restriction enzyme by GenScript® (USA) in an E. coli TOP10-strain 
glycerol stock. To facilitate cloning, both gene variants contained 5’ BspHI and 3’ XhoI 
restriction enzyme cut sites on the proximal ends of the gene. For downstream protein 
detection and purification purposes, a 6xHis-tag was fused to the 3’ termini of the gene 
variants separated by a linker sequence (Fig. 2.1) – 5’ GAG GCT GCT GCA AAG GCT 3’. The 




Figure 2.1: Synthesised CHIKV E2 glycoprotein gene variant constructs. Each variant contains a 
5’ BspHI and 3’ XhoI restriction enzyme site, and a 3’ polyhistidine tag (6xHIS) separated from the 
gene by a linker. The CHIKV E2ΔTM gene variant lacks the transmembrane domain (TM). The 
synthesised CHIKV E2-HIS construct is 1319 bp in length and the CHIKV E2ΔTM-HIS construct is 




2.2.2 Cloning and Plant Expression Vectors 
The pUC57 (containing CHIKV E2 gene variants synthesised and cloned by GenScript®, 
USA as pUC57-CHIKV E2-HIS and pUC57-CHIKV E2ΔTM-HIS), pUC18-LPH (Biopharming 
Research Unit, University of Cape Town; see 2.2.3.4) and pJET1.2/blunt (CloneJET PCR 
Cloning Kit, Thermo Fisher Scientific; see 2.2.3.5) cloning vectors were used for cloning 
purposes.  
The vectors pEAQ-HT (Prof. G Lomonossoff, John Innes Centre, Norwich) and pTRAkc-
ERH (Dr Rainer Fischer, Fraunhofer Institute for Molecular Biology and Applied Ecology, 
IME, Germany) (Fig. 2.2) were used for subcloning of the two gene variants and 
subsequent transient plant expression. The vectors and their antibiotic resistance 
markers are summarised in Table 2.1. 
 
Figure 2.2: Plant expression vectors pTRAkc-ERH and pEAQ-HT used in this study. CaMV 35S, 
Cauliflower mosaic virus 35S promoter; ColE1ori, origin of replication for E. coli; nptII, kanamycin-
resistance gene; LPH, signal-peptide sequence; SEKDEL, ER-retention signal sequence; RK2ori, 
origin of replication for A. tumefaciens; bla, ampicillin- and carbenicillin-resistance gene; p19, 
tomato bushy stunt-virus RNA-silencing suppressor; NcoI/AgeI/XhoI, restriction-enzyme sites for 
gene insertion. 
 
Table 2.1: A summary of vectors used in this study. 
VECTOR BACTERIAL STRAIN ANTIBIOTIC, WORKING 
CONCENTRATION 




pUC18-LPH E. coli DH5α 
 
Ampicillin, 100 μg/mL 
pJET1.2/blunt E. coli DH5α 
 
Ampicillin, 100 μg/mL 
pEAQ-HT E. coli DH5α Kanamycin, 50 μg/mL 
 
 A. tumefaciens 
LBA4404 
 
Rifampicin, 50 μg/mL 
Kanamycin, 30 μg/mL 




Ampicillin, 100 μg/mL 
 
Rifampicin, 50 μg/mL 
Carbenicillin, 50 μg/mL* 
Kanamycin, 30 μg/mL 
 
* The GV3101:pMP90RK strain is a rifampicin- and kanamycin-resistant strain; however, upon 
generation of the recombinant clone, the clone gains additional carbenicillin resistance.  
 
2.2.3 Cloning Strategy 
2.2.3.1 General Cloning 
CHIKV E2-HIS and CHIKV E2ΔTM-HIS were isolated from their pUC57 vectors for 
subsequent ligation into vectors. Vectors were linearised with appropriate restriction 
enzymes, resolved by 1% agarose gel electrophoresis and gel purified. Ligations of gene 
variants into vectors were facilitated by T4 DNA ligase (New England Biolabs) as per the 
manufacturer’s instructions and incubated O/N at 4 oC. Thereafter, O/N ligation reactions 
were transformed into E. coli DH5α (E. cloni® 10G cells, Lucigen). Transformed bacterial 
suspensions were plated on LB agar plates with appropriate antibiotics and incubated at 
37 oC O/N. Bacterial colonies were screened to confirm successful ligation and 
transformation by colony polymerase chain reaction (PCR) screening using appropriate 
primers. Colony PCR was performed using Ampliqon Taq DNA Polymerase (Ampliqon, 
Denmark) as per the manufacturer’s instructions and resolved and analysed by 1% 
agarose gel electrophoresis. Primer names and sequences used in this study are 
summarised in Table 2.2. Plasmids were isolated from selected positive colonies and 
digested with appropriate restriction enzymes to confirm positive colony PCR results 
(single digest-control reactions were performed in the same buffer to that of double 
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digest reactions to ensure correct functionality of the individual restriction enzymes in 
the double digest reactions). If gene variants were cloned into an intermediary vector 
(pUC18-LPH or pJET1.2/blunt), the general cloning process was repeated for final cloning 
into the plant expression vector pEAQ-HT; however, for repetition of this process, like 
isolation of gene variants from pUC57 they were isolated from their intermediary vector 
instead in preparation for subsequent ligations.  
 
 
Table 2.2: Summary of primers used in this study.  
PRIMER DIRECTION NUCLEOTIDE SEQUENCE PURPOSE 
PTRA-F Forward 5’-CAT TTC ATT TGG AGA 




PTRA-R Reverse 5’-GAA CTA CTC ACA CAT 






AGEI-LPH-F Forward 5’-ATA CCG GTC ATT TCA 
TTT GGA GAG GAC ACG-
3’ 
 
Colony PCR; Gene 
amplification 
 








PJET1.2-F Forward 5’-CGA CTC ACT ATA 
GGG AGA GCG GC-3’ 
 
Sequencing 
PJET1.2-R Reverse 5’-AAG AAC ATC GAT TTT 
CCA TGG CAG-3’ 
 
Sequencing 
M13-F Forward 5’-CGC CAG GGT TTT 
CCC AGT CAC GAC-3’ 
 
Colony PCR 
M13-R Reverse 5’-GAG CGG ATA ACA 
ATT TCA CAC AGG-3’ 
Colony PCR 




2.2.3.2 Isolation of gene variants 
pUC57 CHIKV E2-HIS and pUC57 CHIKV E2ΔTM-HIS glycerol stocks were streaked onto 
Luria-Bertani (LB) agar plates supplemented with appropriate antibiotics (Table 2.1) and 
incubated at 37 oC overnight (O/N). A single colony containing each pUC57 construct was 
cultured in LB broth with appropriate antibiotics and incubated at 37 oC O/N, with 
agitation. pUC57-plasmid DNA was isolated using a QIAprep® Spin Miniprip Kit (Qiagen, 
Germany) as per the manufacturer’s instructions. Thereafter, the gene variants were 
excised from their respective pUC57 plasmids by triple restriction enzyme digest with 
restriction enzymes BspHI and XhoI (Thermo Fisher Scientific), the two synthesised 
enzyme restriction sites framing the gene variants, and AflIII (Thermo Fisher Scientific). 
A double digest with BspHI and XhoI would have resulted in two identically sized 
fragments (one being the gene variants and one being a fragment from the vector 
backbone). Therefore, AflIII was used in these digests to cut the pUC57-vector backbone 
to ensure all fragments were different sizes for downstream gel purification of just the 
gene variant DNA fragments. The digested DNA was resolved by 1% agarose gel 
electrophoresis using a Tris-Borate-EDTA (TBE) buffer supplemented with 2 mg/mL of 
ethidium bromide for visualisation. The O’Gene Ruler™ 1kb DNA Ladder (Thermo Fisher 
Scientific) was used for size comparison of DNA fragments. The resolved gene variants 
were subsequently gel purified using the QIAquick® Gel Extraction kit (Qiagen, Germany) 
as per the manufacturer’s instructions.  
Each of the purified gene variants were then ligated into their destination expression 
vectors in this order: 
 pTRAkc-ERH cloning strategy (Fig. 2.3): pUC57 → pTRAkc-ERH 
 Original pEAQ-HT cloning strategy (Fig. 2.4): pUC57 → pUC18-LPH → pEAQ-HT 
(pEAQ-HT lacks an LPH signal-peptide sequence, thus, a subcloning step into 
pUC18-LPH was performed to add the LPH signal-peptide sequence onto the 5’ 
terminus of the gene variants) 
 New pEAQ-HT cloning strategy (Fig. 2.5): pTRAkc-ERH LPH CHIKV E2-HIS and LPH-




2.3.3.3 pTRAkc-ERH cloning strategy 
The isolated gene variants were ligated into the pTRAkc-ERH vector (insert:vector ratio 
of 5:1), previously cut with NcoI (compatible with BspHI) and XhoI, adding an LPH ER 
signal-peptide sequence onto the 5’ termini of the gene variants. After colony PCR 
screening, a positive clone was further confirmed by sequencing (Macrogen, Inc., South 
Korea). Both colony PCR screening and sequencing used pTRA-F and pTRA-R primers 
(Table 2.2). A summary of this cloning process can be seen in Fig. 2.3. 
Confirmed pTRAkc-ERH LPH-CHIKV E2-HIS and pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS 
constructs were transformed into electrocompetent A. tumefaciens GV3101:pMP90RK 
cells. Three hundred nanograms of DNA was added to 100 μL of electrocompetent cells 
in a chilled 0.1 cm electroporation cuvette (Molecular BioProducts, Inc.). The DNA and 
cells were mixed slowly and chilled on ice for 5 minutes. Cells were electroporated using 
parameters of 1.8 kV, 25 μF and 200 Ω; thereafter 900 μL of LB was transferred to the 
cells which were incubated at 27 oC for 2 hours. One hundred microlitres of transformed 
bacterial suspension was plated on LB agar plates with appropriate antibiotics. All LB agar 
plates were incubated at 27 oC for 3 days. Recombinant Agrobacterium colonies were 







Figure 2.3: Summary of the cloning strategy to generate pTRAkc-ERH plant expression vectors 
harbouring the CHIKV E2 gene variants. The CHIKV E2 gene variants were excised from the 
pUC57 vector using restriction enzymes BspHI and XhoI, purified and subsequently ligated into 




2.2.3.4 Original pEAQ-HT Cloning Strategy 
pEAQ-HT lacks an LPH signal-peptide sequence, thus, a subcloning step into pUC18-LPH 
(insert:vector ratio of 5:1) cut with NcoI (compatible with BspHI) and XhoI was necessary 
to fuse the LPH signal-peptide sequence onto the 5’ terminus of the gene variants. In this 
strategy, the isolated gene variants were ligated into the pUC18-LPH vector and screened 
by colony PCR in order to isolate a clone containing LPH-fused gene variants. However, 
generation of pUC18 LPH-CHIKV E2-HIS and pUC18 LPH-CHIKV E2ΔTM-HIS was 
unsuccessful, despite multiple attempts (Fig. 2.12). A summary of the proposed cloning 












Figure 2.4: Summary of the cloning strategy to generate pEAQ-HT plant expression vectors 
harbouring the CHIKV E2 gene variants. The CHIKV E2 gene variants were excised from the 
pUC57 vector using restriction enzymes BspHI and XhoI, purified and subsequently ligated into 
pUC18-LPH previously cut with NcoI) and XhoI. The LPH-fused gene variants were then excised 
from the pUC18-LPH plasmid using restriction enzymes AgeI and XhoI, purified and subsequently 
ligated into pEAQ-HT previously cut with AgeI and XhoI. *, E2 or E2ΔTM. 
 
2.2.3.5 New pEAQ-HT Cloning Strategy 
Consequently, an alternative strategy was devised to clone CHIKV E2-HIS and CHIKV 
E2ΔTM-HIS into pEAQ-HT: the LPH-fused gene variants in the successfully-generated 
pTRAkc-ERH constructs (Fig. 2.10 and 2.11) were amplified by PCR using the pTRA-F 
primer with a 5’ AgeI-sequence overhang (AgeI-LPH-F) and the pTRA-R reverse primer 
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(Table 2.2). An AgeI restriction cut site was added onto the 5’ terminus of the gene 
variants, as a result, to facilitate downstream ligation of the amplified gene variants into 
pEAQ-HT. The CloneJET PCR Cloning Kit (Thermo Fisher Scientific) was used for 
amplification and subsequent subcloning of the amplified fragments into an 
intermediate pJET1.2/blunt vector according to the manufacturer’s instructions to yield 
pJET1.2 AgeI-LPH CHIKV E2-HIS-pTRA-R and pJET1.2 AgeI-LPH CHIKV E2ΔTM-HIS-pTRA-R. 
Sequencing of pJET1.2 constructs was performed using pJET1.2-vector primers in Table 
2.2. Following this, the isolated LPH-fused gene variants were excised out of the pJET1.2 
constructs using AgeI and XhoI and inserted into pEAQ-HT (insert:vector ratio of 10:1) 
cut with AgeI and XhoI and dephosphorylated using rApid Alkaline Phosphatase (Roche) 
as per the manufacturer’s instructions. For the new strategy, to rule out erroneous 
digestion and ligation steps as potential causes for the cloning issues seen in the original 
pEAQ-HT cloning strategy, a sample of the AgeI- and XhoI-digested pEAQ-HT vector was 
resolved by agarose gel electrophoresis (as described in 2.2.3.2) to ensure the vector was 
correctly digested in preparation for ligations of LPH-CHIKV E2-HIS gene variants. 
Likewise, samples of the subsequent ligation reactions of pJET1.2-isolated LPH-CHIKV E2-
HIS gene variants were resolved by agarose gel electrophoresis to ensure correct 
ligations of gene variant isolates into the digested pEAQ-HT vector. The efficiency of 
these digests and ligations were screened before transformations. One microlitre of O/N 
ligation reactions were screened by PCR to investigate whether the recombinant pEAQ-
HT LPH-CHIKV E2-HIS and pEAQ-HT LPH-CHIKV E2ΔTM-HIS constructs were generated 
successfully. Colonies were screened for positive clones by colony PCR.  A summary of 
this cloning process can be seen in Fig. 2.5. Clones pJET1.2 LPH-CHIKV-E2-HIS and Clones 












Figure 2.5: Summary of the cloning strategy to generate pEAQ-HT plant expression vectors 
harbouring the CHIKV E2 gene variants.The LPH-fused CHIKV E2 gene variants were amplified 
out of the pTRAkc-ERH LPH-CHIKV E2*-HIS constructs using the AgeI-LPH-F and pTRA-R primers, 
fusing a 5’ AgeI sequence onto the gene variants, purified and subsequently ligated into 
pJET1.2/blunt vector previously blunt-end cut with EcoRV. The LPH-fused gene variants were 
then excised from the pJET1.2 plasmid using restriction enzymes AgeI and XhoI, purified and 
subsequently ligated into pEAQ-HT previously cut with AgeI and XhoI. *, E2 or E2ΔTM.   
 
2.2.3 Small-Scale Agroinfiltration Expression Time-Trials 
A. tumefaciens harbouring pTRAkc-ERH LPH-CHIKV E2 and pTRAkc-ERH LPH-CHIKV 
E2ΔTM were cultured in 10 mL LB media with appropriate antibiotics (Table 2.1) O/N at 
27 oC with agitation (220 rpm). Thereafter, a 50 mL LB Broth base (2.5 g/L tryptone, 12.5 
g/L yeast extract, 5 g/L NaCl, 1.95 g/L MES, pH 5.6) was inoculated with the O/N 10 mL 
LB culture with appropriate antibiotics (except rifampicin) and supplemented with 5 μL 
of 200 mM acetosyringone. The inoculated 50 mL culture was incubated as above.  
Subsequently, the concentration of the O/N culture was determined, using a 600 nm 
wavelength, and supplemented with resuspension solution (0.97 g/L MES, 2.03 g/L 
MgCl2, pH 5.6) to achieve the desired optical density (OD600) of 1.0 and 0.5, and 200 mM 
acetosyringone added to a final concentration of 20 μM. The resuspended cultures were 
left at room temperature (RT) for an hour prior to syringe infiltration to allow for 
induction of the vir genes by the acetosyringone.  A. tumefaciens strains containing 
pTRAkc-ERH lacking any gene of interest (OD600 = 0.5) and pEAQ-HT Shuni-HIS (OD600 = 
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0.5)(Verbeek, 2019) were cultured, resuspended and infiltrated as above for use as 
negative and positive HIS controls, respectively.  
Each resuspension was syringe infiltrated into the abaxial surface of three four to six-
week old N. benthamiana plant leaves (grown under 16-h artificial light/ 8-h dark cycles, 
at 25 oC, 45% relative humidity). 
A subsequent expression time trial was performed to investigate the effects that co-
expressing human chaperone proteins, calreticulin (CRT) and calnexin (CNX), and plant 
RNA-silencing suppressor NSs have on CHIKV E2-HIS and CHIKV E2ΔTM-HIS expression 
levels. pTRAkc-ERH LPH-CHIKV E2 and pTRAkc-ERH LPH-CHIKV E2ΔTM were co-expressed 
with constructs encoding CRT, CNX or NSs. Constructs pEAQ-HT CRT (E. Margolin, 
Biopharming Research Unit, University of Cape Town), pEAQ-HT CNX (E. Margolin, 
Biopharming Research Unit, University of Cape Town) and pBIN-NSs (Takeda et al., 2002) 
were cultured and prepared for infiltration as above. Their respective ODs, 




Table 2.3: A summary of additional constructs used in this study to increase recombinant 
CHIKV E2 protein variant expression. Construct name, their optical densities in infiltration 








pEAQ-HT CRT 0.5 AGL-1 Kanamycin, 50 μg/mL 
Carbenicillin, 25 μg/mL 
pEAQ-HT CNX  0.5 AGL-1 Kanamycin, 50 μg/mL 
Carbenicillin, 25 μg/mL 
pBIN-NSs 0.5 LBA4404 Kanamycin, 30 μg/mL 




2.2.4 Small-Scale Protein Extraction and Quantification of recombinant 
proteins 
Infiltrated plants were grown under the conditions described in 2.2.3 for 7 days post-
infiltration (dpi). Leaf-disks were sampled on days 3, 5 and 7 dpi using the cap of a 2 mL 
Eppendorf reaction tube. Three leaf-disks were harvested (one clipping per leaf 
infiltrated) per construct per dpi per OD. Tubes containing leaf-disks were stored at -80 
oC until further processed.  
Once all samples had been harvested, leaf-disks were thawed at RT. Subsequently, 200 
μL of 1xPBS supplemented with protease inhibitor (cOmplete™, EDTA-free Protease 
Inhibitor Cocktail, Roche) and a 60 mm diameter ceramic bead (Merck and Co, 
Kenilworth, USA) were added to each 2 mL Eppendorf tube containing the thawed leaf-
disk samples. Tubes were subsequently added to a vortex mixer shaking at the highest 
setting at 4oC until plant material was sufficiently pulverised. Pulverised samples were 
then centrifuged for 15 000 x g for 10 mins to pellet insoluble material and supernatants 
were transferred to a new 1.5 mL Eppendorf reaction tube to be prepared for resolution 
by SDS-PAGE (see section 2.2.5). Denatured crude extract samples were then stored at -
20 oC until analysis.  
Prior to crude extract sample resolution by SDS-PAGE, samples were quantitated using a 
Bradford assay (BioRad). The standard curve, from which protein sample concentrations 
were calculated, was generated using a range of known bovine serum albumin (BSA) 
concentrations.  All samples and standards were measured in triplicate.  
 
2.2.5 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Protein samples were prepared by adding 5 x sample application buffer (SAB) comprising 
of 94 mM Tris-Cl pH 7.5, 1.9 mM EDTA, 10% SDS, glycerol and bromophenol blue to a 
final dilution of 1:5. If samples had previously been stored at -80 oC, they were thawed 
at room temperature before the addition of 5 x SAB. Thereafter, the samples were 
denatured at 95 oC for 10 mins. Equal amounts of Denatured total soluble protein (TSP) 
were resolved by 10% SDS-PAGE at 120 V by means of BioRad Mini-Protean© Tetra Cell 
Systems (BioRad Laboratories, Hercules, USA) electrophoresis equipment.   
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For Coomassie staining, Coomassie brilliant blue stain (0.1% (m/v) Brilliant Blue R-250, 
50% (v/v) glacial acetic acid and 10% (v/v) glacial acetic acid) was used to stain resolved 
samples at 37 oC for 1 hour prior to submerging the gel in destaining solution (45% (v/v) 
methanol, 10% (v/v) glacial acetic acid) O/N at room temperature with agitation.  
 
2.2.6 Western Blotting 
Following electrophoresis of equal TSP by SDS-PAGE, expression of recombinant plant-
produced proteins was analysed by Western blot. The resolved proteins were transferred 
onto a nitrocellulose membrane (Amersham™ Protran™ Premium 0.45 μm NC) at 15 V 
for 90 mins using a Bio-Rad Trans-Blot Semi-dry transfer blotter (Bio-Rad Laboratories, 
Hercules, USA). Thereafter, the membrane was blocked using blocking buffer (5% (v/v) 
skim milk, 10% (v/v) 10xPBS, 0.1% (v/v) 10% Tween 20) for 30 mins at RT and then probed 
with mouse-produced primary anti-6xHis antibody (Thermo Fisher Scientific) diluted (1/2 
000) in blocking buffer at 4 oC O/N with agitation. Following this, the membrane was 
washed with blocking buffer for 15 mins x 4. Diluted (1/10 000) goat-produced secondary 
alkaline phosphatase-conjugated antibody was used to probe the membrane for 1 hr at 
37 oC with subsequent washes using blocking buffer without milk for 15 mins x 4. Probed 
proteins were detected using nitro-blue tetrazolium and 5-bromo-4-chloro-3'-
indolylphosphate (NBT/BCIP; SeraCare Life Sciences Inc., Milford, USA). Rabbit-produced 
primary anti-CRT (abcam, Cambridge, United Kingdom), anti-RuBisCo (BIOCOM biotech, 
South Africa) and their goat-produced anti-rabbit secondary antibodies were diluted (1/5 
000, 1/10 000, 1/10 000, respectively) and used as above.  
 
2.2.7 Large-Scale Vacuum Agroinfiltration  
Ten mL of LB media was inoculated with a glycerol stock of the recombinant A. 
tumefaciens harbouring the pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS and pEAQ-HT CRT 
constructs with appropriate antibiotics. The cultures were incubated at 27 oC O/N with 
agitation. Thereafter, 50 mL LBB media was inoculated with the 10 mL O/N cultures with 
appropriate antibiotics and incubated O/N at 27 oC with agitation. The following day, 500 
mL LBB media was inoculated with the 50 mL O/N cultures. The final inoculated culture 
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was supplemented with appropriate antibiotics, except rifampicin, and 200 mM 
acetosyringone to a final concentration of 20 μM. The cultures were incubated as above. 
On the day of infiltration, the OD600 of the cultures were determined and subsequently 
supplemented with resuspension media, to the desired respective OD600, and 200 mM 
acetosyringone to a final concentration of 200 μM. Leaves were harvested on 5 dpi and 
stored at -80 oC for large-scale protein extraction (see section 2.2.8) 
 
2.2.8 Large-Scale Protein Extraction 
Harvested leaves from -80 oC storage were homogenised, without thawing, in 1 x PBS (2 
mL/g leaf material) supplemented with protease inhibitor, at first, using an Ultra-Turrax® 
homogeniser (IKA® Works Inc., NC, USA). Thereafter, crude extract was agitated at 4 oC 
for 60 mins and then filtered through MiraclothTM (22-24 μm pore, Millipore, USA). The 
filtrate was centrifuged at 10 000 rpm for 15 mins at 4 oC and the supernatant was either 
stored at -80 oC or denatured (see section 2.2.5 at 95 oC for 10 mins. 
 
2.2.9 Stability Studies  
Once the optimal conditions of recombinant CHIKV E2 protein variant expression were 
chosen, it was worth investigating the stability of the chosen protein variant at -80 oC 
over time for the utilisation of the protein for incorporation into a diagnostic kit. 
Additionally, the stability of the protein variant was investigated with and without 
protease inhibitor as prolonged stability of a protein in an extraction buffer without 
protease inhibitor lessens the DSP costs. Proteins were extracted, as described in 2.2.8, 
with and without protease inhibitor (PI), from harvested leaves after large-scale vacuum 
infiltration. Three 100 µL samples for each type of crude extract (with PI and without PI) 
were transferred to an Eppendorf reaction tube and stored at -80 oC. One sample from 
each crude extract type was stored for 30, 60, and 90 days and thawed and denatured, 
as described in 3.2.3, on their allocated day. Once all samples were denatured and stored 





2.3.1 Confirmation of Plant Expression Constructs 
2.3.1.1 pTRAkc-ERH expression constructs 
The CHIKV E2-HIS and CHIKV E2ΔTM-HIS gene variants were subcloned into pTRAkc-ERH. 
Confirmation of successful cloning and transformation was confirmed by colony PCR 
screening (Fig. 2.9), restriction digest analysis (Fig. 2.10) and sequencing (data not 
shown).  
 
Figure 2.9: Colony PCR screening of recombinant pTRAkc-ERH E. coli transformants. Five 
colonies per construct were screened using pTRA-vector primers (Table 2.2). Expected PCR 
product sizes for pTRAkc-ERH LPH-CHIKV E2-HIS colonies were 1543 bp and for pTRAkc-ERH LPH-
CHIKV E2ΔTM-HIS colonies 1366 bp. +ve, pUC57-CHIKV E2-HIS and pUC57-CHIKV E2ΔTM-HIS 
colony-PCR positive controls; -ve, no-template negative control; M, O’GeneRuler™ 1kb DNA 
Ladder. White arrows, constructs selected for restriction enzyme digest analysis.  
 
Of the colonies screened for pTRAkc-ERH LPH-CHIKV E2-HIS, 4 out of 5 showed the 
expected fragment of 1543 bp. For pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS, 2 out of 5 
colonies showed the expected fragment of 1366 bp. DNA was extracted from two 
colonies per construct (white arrows, Fig. 2.9) for restriction enzyme digest analysis to 





Figure 2.10: Restriction enzyme digest of recombinant pTRAkc-ERH constructs. DNA from two 
colonies per construct was double digested with PstI and XhoI or cut with NcoI. Undigested-
vector reactions were used as a control. An expected band size for the double digest of pTRAkc-
ERH LPH-CHIKV E2-HIS and pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS are 1332 bp and 1155 bp, 
respectively, with a 7598 bp vector backbone. M1k, O’GeneRuler™ 1kb DNA Ladder; M100, 
O’GeneRuler™ 100 bp Plus DNA Ladder.  
 
Constructs digested with PstI and XhoI (two restriction sites framing the inserted gene) 
resulted in DNA fragments of the expected sizes of 1332 bp and 1155 bp for pTRAkc-ERH 
LPH-CHIKV E2-HIS and pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS, respectively. In addition, 
NcoI-digested and undigested constructs displayed identical banding patterns, indicating 
the abolishment of the vector’s MCS NcoI site during the ligation of the pTRAkc-ERH NcoI 
site’s compatible end with the gene variant’s BspHI site’s compatible end. Confirmed 
pTRAkc-ERH LPH-CHIKV E2-HIS and pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS DNA were 
electroporated into Agrobacterium strain GV3101::pMP90RK and screened by colony 





Figure 2.11: Colony PCR screening of recombinant pTRAkc-ERH Agrobacterium transformants. 
Nine colonies per electroporated construct were screened using pTRA-vector primers (Table 2.2). 
Expected PCR product sizes for pTRAkc-ERH LPH-CHIKV E2-HIS colonies are 1543 bp and for 
pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS colonies are 1366 bp. +ve, positive transformed E. coli 
pTRAkc-ERH colonies; -ve, no-template negative control; M, O’GeneRuler™ 1kb DNA Ladder. 
White arrows, colonies sent for sequencing (data not shown) and used for downstream 
expression studies.   
 
All recombinant pTRAkc-ERH LPH-CHIKV E2-HIS colonies yielded an amplified fragment 
of 1543 bp. Similarly, amplification of all recombinant pTRAkc-ERH LPH-CHIKV E2ΔTM-
HIS colonies yielded an expected fragment of 1366 bp size.  
The extracted pTRAkc-ERH LPH-CHIKV E2-HIS and pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS 
constructs were sequenced and confirmed successful cloning of the CHIKV E2 gene 
variants in pTRAkc-ERH (data not shown). These constructs were used for downstream 
transient-expression time trials of CHIKV E2 protein variants.   
 
 
2.3.1.2 pEAQ-HT Expression Constructs  
2.3.1.2.1 Original Cloning Strategy Results 
Both gene variants were ligated into pUC18-LPH, constructs were transformed into E. 
coli and clones were screened by colony PCR. Representative data is shown in Fig. 2.12. 
As can be seen, all but one of the screened colonies yielded bands identical in size to that 
of the pUC18-LPH vector lacking the insert indicating that ligation and/or transformation 
was unsuccessful. Colony 1 of the pUC18-LPH CHIKV E2ΔTM-HIS clones yielded a product 
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lower than the empty pUC18-LPH control. This may be due to non-specific binding of 
primers to supplied template DNA.  
 
Figure 2.12: Colony PCR screening of recombinant pUC18-LPH E. coli transformants. Five 
colonies per transformed construct were screened using M13 primers (Table 2.2). Expected PCR 
product sizes for pUC18-LPH CHIKV E2-HIS colonies were 1512 bp and for pUC18-LPH CHIKV 
E2ΔTM-HIS colonies are 1335 bp. +ve, pUC57-CHIKV E2-HIS and pUC57-CHIKV E2ΔTM-HIS 
colony-PCR positive controls; -ve, no-template negative control; M, O’GeneRuler™ 1kb DNA 
Ladder.  
 
2.3.1.2.1 New Cloning Strategy Results 
The original pEAQ-HT strategy described in 2.2.3.4 was to generate the LPH-fused gene 
variants for subsequent subcloning into the plant expression vector pEAQ-HT; however, 
as this was unsuccessful, a new strategy was devised. LPH-CHIKV E2-HIS and LPH-CHIKV 
E2ΔTM-HIS were amplified and isolated, to yield correctly sized products indicative of  
successful isolation of LPH-fused CHIKV E2-HIS variants (data not shown), and cloned into 
an intermediary vector (pJET1.2/blunt) to generate pJET AgeI-LPH CHIKV E2-HIS-pTRA-R 
and pJET AgeI-LPH CHIKV E2ΔTM-HIS-pTRA-R 
PCR screening of transformed E. coli colonies and sequencing (data not shown) of DNA 
prepared from the putative recombinants indicated successful transformation of pJET1.2 
constructs. The 1473 bp and 1296 bp amplified products obtained from 4 out of 5 
colonies screened represent amplified LPH-CHIKV E2-HIS and LPH-CHIKV E2ΔTM-HIS 
from the transformed pJET1.2 constructs using the AgeI-LPH-pTRA-F and pTRA-R primers 




   
Figure 2.13: Colony PCR of pJET1.2 E. coli transformants. Six colonies per transformed construct 
were screened using AgeI-LPH-F and pTRA-R primers (Table 2.2). Expected PCR product sizes for 
pJET1.2 AgeI-LPH CHIKV E2-HIS-pTRA-R colonies are 1473 and for pJET1.2-AgeI-LPH CHIKV 
E2ΔTM-HIS-pTRA-R colonies are 1296 bp. -ve, no-template negative control; +ve, pJET1.2 West 
Nile Virus (WNV) AgeI-LPH-Envelope (Env)-pTRA-R positive control (~ 1.8 kb); M, O’GeneRuler™ 
1kb DNA Ladder. White arrows, colonies from which DNA was used for sequencing. 
 
As mentioned in section 2.2.3.5, a sample of the AgeI- and XhoI-digested pEAQ-HT vector 
was resolved by agarose gel electrophoresis to ensure apt digestion of the vector before 
performing ligations of LPH-CHIKV E2-HIS gene variants (Fig. 2.14A). Single digest control 
reactions of the pEAQ-HT vector showed that the respective restriction enzymes cut 
correctly. Therefore, since the single digests cut correctly in the same buffer used for the 
double digest, it can be inferred that the respective enzymes cut pEAQ-HT correctly 
during the double digest i.e. the digestion of pEAQ-HT with AgeI and XhoI in preparation 
for ligations was performed correctly.   
 Samples of the subsequent ligation reactions were also resolved by agarose gel 
electrophoresis to ensure LPH-CHIKV E2-HIS gene variants successfully ligated into 
phosphorylated and/or dephosphorylated variants of the digested pEAQ-HT vector (Fig. 
2.14B) before performing transformations. The 1415 bp size bands in lanes 2 and 4 
indicated that only the LPH-CHIKV E2ΔTM-HIS gene variant ligated into digested pEAQ-
HT vectors (dephosphorylated and non-dephosphorylated). However, an unknown ~800 
bp size band was amplified in these reactions. In addition, PCR screening predominantly 
amplified fragments identical to those seen in the empty vector control (E) indicating a 
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higher number of unsuccessful ligations present compared to the number of successful 
ligations present in the ligation reactions. Transformations of these ligation reactions 
were performed despite these results.  
Colony PCR screening of E. coli transformed with pEAQ-HT constructs identified no 
positive clones (Fig. 2.14C). PCR screening of the clones amplified fragments that are 
identical to pEAQ-HT constructs lacking the ligated LPH-CHIKV E2-HIS gene variants of 
interest (“Empty pEAQ-HT”).  Despite multiple attempts, the same result was seen 
(data not shown). Therefore, pEAQ-HT LPH-CHIKV E2-HIS and pEAQ-HT LPH-CHIKV 







Figure 2.14: pEAQ-HT cloning analyses. (A) Restriction enzyme digest of empty pEAQ-HT. In 
preparation for ligations, pEAQ-HT vector digests were analysed to confirm correct double and 
single digests with AgeI and XhoI. Undigested pEAQ-HT was added as a control. (B) PCR screening 
of ligation reactions. Ligation efficiency was analysed for the insertion of gene variants into 
either dephosphorylated pEAQ-HT or non-dephosphorylated pEAQ-HT vector digested with AgeI 
and XhoI. 1 µL of ligation reaction mix was analysed using pEAQ-vector primers (Table 2.2). 1, 
LPH-CHIKV E2-HIS → non-dephosphorylated pEAQ-HT vector; 2, LPH-CHIKV E2ΔTM-HIS → non-
dephosphorylated pEAQ-HT vector; 3, LPH-CHIKV E-HIS → dephosphorylated pEAQ-HT vector; 4, 
LPH-CHIKV E2ΔTM-HIS → dephosphorylated pEAQ-HT vector. E, empty pEAQ-HT control. (C) 
Colony PCR screening of pEAQ-HT E. coli transformants. Nine colonies per construct were 
screened using pEAQ-vector primers (Table 2.2). Expected PCR product sizes for pEAQ-HT LPH-
CHIKV E2-HIS were 1592 bp and for pEAQ-HT LPH CHIKV E2ΔTM-HIS are 1415 bp. -ve, no-








2.3.2 Small-Scale Protein-Expression Time Trials 
A small-scale syringe-infiltration time trial was performed over 7 days (see section 2.2.3) 
to determine which of the two CHIKV E2 variants yielded the highest levels of protein, on 
which day post-infiltration (dpi) and at what optical density (OD600 = 0.5 or 1) tested. 
Recombinant cultures harbouring pTRAkc-ERH lacking any insert or pTRAkc-Shuni N-HIS 
(OD600 = 0.5) were used as negative and positive controls, respectively (Fig. 2.15).  
Western blot analyses of equal TSP showed recombinant plant-produced CHIKV E2-HIS 
to be ~52 kDa in size and CHIKV E2ΔTM-HIS to be ~49 kDa in size.  Low to no detectable 
levels of recombinant protein were seen for both CHIKV E2-HIS and CHIKV E2ΔTM-HIS on 
all dpi for both OD600 tested. For CHIKV E2-HIS, at OD600 = 1.0, expression could be seen 
(red arrow) at 3 dpi only; however, it was higher than expression levels observed when 
using an OD600 = 0.5 on the same dpi. Minimal expression was observed for OD = 0.5 at 
5 dpi and no expression was detected on any other day. For CHIKV E2ΔTM-HIS, low levels 
of expression were seen on 3 dpi only for OD600 = 1.0; however, the level of expression 




Figure 2.15: Equal TSP western blot screening of pTRAkc-ERH LPH-CHIKV E2-HIS (left) and 
pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS (right) expression. Expression time trial of CHIKV E2 gene 
variants at OD600 1.0 and 0.5 over a 7-day period. Nitrocellulose membrane was probed with anti-
HIS antibodies. M, MW marker; red arrow, expected size of CHIKV E2ΔTM-HIS; -ve, empty 




Thereafter, the CHIKV E2 gene variants were co-expressed with either CRT (OD600 = 0.5), 
CNX (OD600 = 0.5), NSs (OD600 = 0.5) to determine whether this increased protein 
expression.  
Co-expression of pTRAkc-ERH LPH-CHIKV E2-HIS with either CRT, NSs or CNX showed 
higher levels of expression on select dpi than that without CRT, NSs or CNX and for a 
longer period post-infiltration (Fig 2.16). CRT significantly improves expression for both 
ODs on 5 dpi with little to no detectable improvement of expression outside of this dpi 
for both ODs. Similarly, the other human chaperone, CNX, improves expression slightly 
on 5 dpi for OD600 0.5 and on 7 dpi for OD600 1.0 only. Furthermore, recombinant CHIKV 
E2-HIS expression was significantly better improved by NSs very slightly on 3dpi and 
higher on 5 and 7 dpi for both ODs.  However, these improved levels of expression for 




Figure 2.16: Equal TSP western blot screening of pTRAkc-ERH LPH-CHIKV E2-HIS. Co-expression 
time trial of CHIKV E2-HIS (OD600 = 1.0 and 0.5) with CRT/NSs/CNX (OD600 = 0.5) over a 7-day 
period. Nitrocellulose membrane was probed with anti-HIS antibodies. M, MW marker; red 
arrow, expected size of CHIKV E2ΔTM-HIS; -ve, empty pTRAkc-ERH negative control.  
 
Co-expression of pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS with either CRT, NSs or CNX showed 
higher levels of expression on select dpi than expression without CRT, NSs or CNX and 
for a longer period post-infiltration. Co-expression with CRT increased expression of 
E2ΔTM from being barely visible to a ~ 49 kDa band that is very visible across 3 to 7 dpi 
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using cultures of OD600 = 0.5 and 1.  NSs showed lower expression improvement than 
CRT, but improvement nevertheless, on 3 dpi for both ODs  tested, 5 and 7 dpi for OD600 
= 0.5 as well as 7 dpi for OD600 = 1.0. Interestingly, improvement of expression by NSs 
was better and more prolonged for OD600 = 0.5, compared to OD600 = 1.0, as seen for all 
dpi. Furthermore, CNX improved expression on all dpi for OD600 1.0 and on 3 and 5 dpi 
only for OD600 = 0.5 (Fig. 2.17); however, the improved expression levels were lowest 
compared to improvement by the other co-expressed proteins. Co-expression of 
pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS (OD600 = 1.0) with CRT showed the highest levels of 
expression for any of the conditions investigated, compared also to the co-expression 
time trials of CHIKV E2-HIS. Consequently, these were the conditions chosen scaling up 
expression of the protein. 
 
Figure 2.17: Equal TSP western blot screening of pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS. Co-
expression time trial of CHIKV E2ΔTM-HIS (OD600 = 1.0 and 0.5) with CRT/NSs/CNX (OD600 = 0.5) 
over a 7-day period. Nitrocellulose membrane was probed with anti-HIS antibodies. M, MW 
marker; red arrow, expected size of CHIKV E2ΔTM-HIS; -ve, empty pTRAkc-ERH negative control. 
 
2.3.3 Large-Scale Vacuum Infiltration  
A scaled-up co-infiltration time-trial repeat of pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS (OD600 
= 1.0) and pEAQ-HT CRT (OD600 = 0.5) was performed on 15 plants (5 plants per dpi). 
Western blot screening of crude extract equal TSP indicated the highest expression levels 
of CHIKV E2ΔTM-HIS on 3 dpi (Fig. 2.18 red arrow); however, a faint, similarly-sized signal 
was detected in the crude extract of plants infiltrated with CRT only (Fig.2.18, “CRT only” 
lane) indicating possible non-specific probing. Additionally, Coomassie staining of the 
same samples showed the resolution of a similarly-sized protein to that of CHIKV E2ΔTM-
HIS (~53 kDa) in all samples (‘CRT only’ included) (Fig. 2.18 yellow arrows). This protein 
signal of similar size was worth investigating as it may indicate that the signal we saw 
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from probing CHIKV E2ΔTM-HIS might have been non-specific probing of the anti-6xHis 
antibodies to either the similar-sized large RuBisCo subunit (~53 kDa), CRT (~49 kDa) or 




Figure 2.18: Equal TSP western blot screening (top) and Coomassie staining (bottom) of 
pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS. Repeat of the co-expression time trial, on a large-scale, of 
CHIKV E2ΔTM-HIS (OD600 = 1.0) with CRT (OD600 = 0.5) over a 7-day period to select optimal dpi 
for large-scale harvesting. Nitrocellulose membrane was probed with anti-HIS antibodies. M, 
MW marker; red arrow, expected size of CHIKV E2ΔTM-HIS; yellow arrows, CHIKV E2ΔTM-
HIS/CRT/large subunit of RuBisCo; +ve, Shuni N-HIS positive anti-HIS control. 
 
Coomassie staining of 3 dpi crude extract samples from large-scale co-expression of 
CHIKV E2ΔTM-HIS and CRT expression only and empty pTRAkc-ERH show a set of 
dominantly expressed proteins resolving between the ¬50 kDa and ¬55 kDa marks (Fig. 
2.19). Western blot screening of the same samples indicated no background signal as a 
result of non-specific binding of anti-HIS antibodies as seen in lane “2” where both CRT 
and the large subunit of RuBisCo is present (as seen by the αRuBisCo and αCRT blots). 
This may indicate that the signal seen in the “CRT only” lane in Fig. 2.18 may have been 
accidental spill-over from lane “7 dpi”. Interestingly, comparing the top-most prominent 
band, in the range observed above, between lane “1” and “2”, CRT levels seem to be 
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higher at the 3-dpi time point when CHIKV E2ΔTM-HIS is not present (“2”). This may 
illustrate the 3 dpi-expression levels of CRT when not actively facilitating the folding of 
CHIKV E2ΔTM-HIS.  
 
 
Figure 2.19: Coomassie staining (left) and equal TSP western blot screening (right) of CHIKV 
E2ΔTM-HIS, CRT and RuBisCo. Repeat of large-scale co-expression of CHIKV E2ΔTM-HIS (OD600  
= 1.0, 3 dpi) with CRT (OD600 = 0.5) to screen for relative CHIKV E2ΔTM-HIS, CRT and RuBisCo 
expression levels and sizes. Identical SDS-PAGE gels were transferred to nitrocellulose 
membranes probed with anti-HIS, anti-CRT and anti-RuBisCo antibodies. M, MW marker; red 
arrow, expected size of CHIKV E2ΔTM-HIS; 1, pTRAkc-ERH CHIKV E2ΔTM-HIS and CRT co-
expression; 2, CRT expression only; -ve, empty pTRAkc-ERH negative control; α-, anti-protein 
antibody.  
 
2.3.4 Stability of CHIKV E2ΔTM-HIS  
Since large-scale co-expression of CHIKV E2ΔTM-HIS and CRT was optimised (Fig. 2.15, 
Fig. 2.17 – 2.19), it was worth investigating the stability of the plant-produced CHIKV 
E2ΔTM-HIS at -80 oC, in the presence or absence of PI in the extraction buffer, over a 90 
day post-extraction (dpe) period, to explore whether and for how long recombinant 
CHIKV E2ΔTM-HIS proteins would be stable at -80 oC for the utilization of these 
recombinant proteins in a diagnostic kit. The results indicated the presence of stable 
CHIKV E2ΔTM-HIS proteins on 30, 60 and 90 dpe in samples extracted with and without 
PI (Fig. 2.20); however, increasing levels of CHIKV E2ΔTM-HIS degradation was observed 
(black arrows) as time increased for samples extracted without PI. Similarly, small levels 
of degradation can be seen for CHIKV E2ΔTM-HIS extracted with PI starting after 60 dpe 
and before 90 dpe; however, these degradation levels are significantly lower than those 





Figure 2.20: Western blot screening of pTRAkc-ERH CHIKV E2ΔTM-HIS. Stability study of 
large-scale extracted CHIKV E2ΔTM-HIS in the presence and absence of protease inhibitor over 
a 90-day period. Nitrocellulose membrane was probed with anti-HIS antibodies. M, MW 
marker; red arrow, expected size of CHIKV E2ΔTM-HIS; black arrow, potential degradation of 
CHIKV E2ΔTM-HIS; -ve, empty pTRAkc-ERH negative control. 
 
2.4 Discussion 
In this study, a consensus sequence of the CHIKV E2 gene generated from three South 
African CHIKV isolates was designed with and without its transmembrane domain (ΔTM) 
with each gene variant containing a 6xHis-tag on their 3’ termini. The consensus 
sequence was generated by using the only three available South African isolates 
mentioned in section 2.2.1. The ORFs of the South African isolates and 77 other isolates 
found around the world are highly conserved; as such, the generated consensus 
sequence represents an appropriate sequence for the diagnostic assay. These constructs 
were codon optimised for optimal expression in the Nicotiana benthamiana plant-
expression host.  
The 6xHis-tag was chosen for its size, the availability of commercial anti-HIS antibodies, 
relative cost compared to other affinity tags, one-step downstream purification process, 
and its low transcriptional/translational burden on the tobacco plant-expression host 
due its small 6 amino-acid size. The plant host is likely to be burdened already as a result 
of transient expression of recombinant proteins of interest via agroinfiltration (Hitzeroth 
and van Zyl, 2016). In addition, at the time this study was being conducted, commercial 
anti-CHIKV E2 antibodies were not readily available. But, as seen by the efficient 
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detection of the 6xHis-tagged CHIKV E2 protein variants, the anti-HIS antibody substitute 
used in this study was a sufficient alternative. Previous studies have shown the efficiency 
of using Ni-NTA chromatography to purify recombinant 6xHIS-tagged CHIKV E2 
glycoproteins in insect (Cho et al., 2008, Bagno et al., 2020), E. coli (Verma et al., 2016, 
Bagno et al., 2020) and mammalian cells (Bagno et al., 2020). These studies present 
further evidence for how the 6xHis-tag and Ni-NTA chromatography provide a universal 
purification system of recombinant antibodies: if recombinant proteins are insoluble, 
located in inclusion bodies and/or have a tertiary structure such that the 6xHis-tag is 
hidden within, proteins can be extracted under denaturing conditions and subsequently 
purified successfully (Crowe et al., 1994).  
The difficulty experienced with the pEAQ-HT cloning may be due to the low amounts of 
correctly-ligated constructs available for transformation and/or the large size of the 
recombinant vector constructs containing the >1 kb gene variant constructs. It is known 
that transformation efficiency decreases with an increase in construct size (Sheng et al., 
1995). The large sizes of genes to be ligated may also account for why insertion into the 
non-dephosphorylated pEAQ-HT vector was unsuccessful. Dephosphorylation of vector 
DNA reduces empty vector background; however, this was not the case as all ligation 
reactions contained similar amounts of empty vector DNA. A combination of these 
factors may be why transforming a construct of >11 kb size into competent cells not 
necessarily designed for this (unlike Maximum-Efficiency DH5α E. coli cells) is failing. 
Transformation of pEAQ-HT constructs into Maximum-Efficiency DH5α E. coli cells, or the 
like, was not performed due to time and cost limitations.  
Cloning of CHIKV E2-HIS and CHIKV E2ΔTM-HIS into pTRAkc-ERH however, was successful 
in generating pTRAkc-ERH LPH-CHIKV E2-HIS and pTRAkc-ERH LPH-CHIKV E2ΔTM-HIS. 
Three small-scale syringe-infiltration time trials (data for one shown) of these constructs 
indicated that the highest yielding CHIKV E2 variant was CHIKV E2ΔTM-HIS (Fig. 2.15, 
2.16). Moreover, western blot analysis of crude extracts from co-expression with either 
CRT, CNX or NSs indicated that the optimal conditions for CHIKV E2ΔTM-HIS expression 
were infiltration at OD600 = 1.0 and co-expression with CRT (Fig. 2.17). Using the optimal 
conditions for large-scale vacuum-infiltration time trials allowed for (a) replication of the 
small-scale infiltration in a large-scale setting and (b) determination of the best dpi to be 
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3 dpi (Fig. 2.18). This is expected as transient protein expression in tobacco plants often 
provides optimal expression within a week; hence sampling leaf clippings at 3, 5 and 7 
dpi. Optimal expression does differ from protein to protein and should be repetitively 
determined on a case-by-case basis: rotavirus capsid protein VP6 (Pera et al., 2015), beak 
and feather disease virus (BFDV) coat protein (Duvenage et al., 2013) and HPV-16 L1 
protein (Maclean et al., 2007) were optimally expressed at 3, 4 and 6 dpi, respectively. A 
similarly-sized signal was seen in the control lanes of Fig. 2.18 (CRT expression only) - this 
is troubling because: (a) as previously mentioned, anti-HIS antibodies are notoriously 
promiscuous and, in this case, are potentially binding non-specifically to a protein(s) of 
similar size; (b) CRT (~49 kDa), CHIKV E2ΔTM-HIS (~52 kDa) and the large subunit of 
ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCo) (~53 kDa) are similar in size 
and, therefore, will resolve similarly by electrophoresis. Therefore, whatever the anti-HIS 
antibodies are potentially non-specifically binding to may be contributing to the signal 
we see for CHIKV E2ΔTM-HIS and thus inflating the observed expression levels assumed 
to only be indicative of CHIKV E2ΔTM-HIS expression levels. Probing of 3 dpi crude 
extracts indicated this not to be the case (Fig. 2.19) and the signal seen is potentially spill 
over from the ‘7 dpi’ lanes (Fig. 2.18). 
Furthermore, a stability study of the same samples as above over a 90-day period was 
performed. While the stability of a protein does not indicate stable biological function, it 
is worth investigating stability as unstable/degraded proteins will not exhibit any 
biological activity. When the biological activity of a protein is assayed, it is worth 
investigating the ideal time of stability to obtain accurate results. The stability study 
indicated stable recombinant CHIKV E2ΔTM-HIS proteins present for at least 90 dpe at -
80 oC. However, increasing levels of degradation were seen for -PI samples over time 
(Fig. 2.20). Therefore, while CHIKV E2ΔTM-HIS can be extracted without PI, thus 
decreasing the cost of DSP, samples need to be processed within a month of extraction 
for optimal DSP yields.   
The small-scale agroinfiltration time-trials and large-scale vacuum agroinfiltrations 
indicated that the transiently expressed CHIKV E2ΔTM-HIS glycoprotein variant, when 
co-infiltrated with human chaperone CRT, is the best expressed variant out of the two 
tested. While this may be so, investigations into the CHIKV E2ΔTM-HIS purification yield 
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must be done to assess and optimisation the most appropriate purification method to 
be used to achieve the highest yield of CHIKV E2ΔTM-HIS glycoproteins for use in the 






















Chapter 3: Purification of CHIKV E2ΔTM-HIS Glycoprotein Variant 
3.1 Introduction  
This chapter describes different techniques used to purify recombinant plant-produced 
CHIKV E2ΔTM-HIS proteins from plant leaf extracts. Downstream processing (DSP), of 
which purification is a component, is the process physical and/or chemical, used to 
extract recombinantly produced proteins from their starting materials. The cost of DSP 
often accounts for up to 80% of the overall biopharmaceutical productions costs 
(Tschofen et al., 2016). Purification of biopharmaceuticals is a critical part of the DSP 
process and must be reliable, robust, easily scaled-up and able to remove impurities 
specific to the protein expression system (Jozala et al., 2016). One such introduced 
process-related impurity is the superabundant plant protein RuBisCo – which may 
require early processing procedures to ensure removal (Tschofen et al., 2016). This may 
be achieved through a partial purification strategy that could potentially separate these 
process-related impurities from CHIKV E2ΔTM-HIS and minor plant proteins. These other 
minor proteins can then be separated from CHIKV E2ΔTM-HIS by a subsequent 
purification strategy that may no longer be hindered by the removed impurities. 
The nickel-affinity purification system is an efficient tool for one-step purification of 
recombinantly produced proteins. The system’s efficiency is credited to the tight-binding 
ability of the fused 6xHis-tag to the immobilised Ni-charged affinity resin (Ni-NTA affinity 
chromatography). As such, it allows for contaminants which are not fused to 6xHis-tags 
and therefore do not bind to Ni-NTA to be washed out under stringent conditions before 
eluting the protein of interest by competition with imidazole, or a slight altering of pH 
(Crowe et al., 1994).  Nickel-affinity purification is a routinely-used system that also offers 
mild-elution conditions – both ideal features for large-scale purification - and the ability 
to purify proteins under denaturing conditions using 8 M urea (Gaberc-Porekar and 
Menart, 2001). One disadvantage that may arise during nickel-affinity purification is the 
lack of binding of a 6xHis-tagged recombinant protein with an inaccessible 6xHis-tag. This 
may lead to low or no binding of the tagged protein to the immobilised resin (Block et 
al., 2009).  
Running a non-denaturing polyacrylamide gel is an informative experiment to perform 
to assess the accessibility of a 6xHis-tag on a recombinant protein. In contrast to 
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denaturing polyacrylamide gel, a non-denaturing gel does not contain the detergent SDS 
and preparation of samples are done without β-mercaptoethanol, SDS and heat-
denaturing conditions (Arndt et al., 2012). This allows for the resolution of the protein of 
interest in its native conformation i.e. the conformation of the protein of interest when 
purified by Ni-NTA affinity chromatography. As such, the exposure of the 6xHis-tag fused 
to the native recombinant protein can be assessed by probing the transferred proteins 
with anti-6xHis antibodies on a nitrocellulose membrane. This should be done in parallel 
with a denatured sample of the same protein of interest to compare the probing signal 
of the denatured and non-denatured samples as a non-exposed 6xHis-tag, when probed 
with anti-6xHis antibodies, will not elicit an BCIP-NBT-facilitated colour reaction as 
intense as the denatured sample. 
Failing efficient one-step purification using Ni-NTA affinity chromatography, pH 
purification and ammonium sulphate ((NH4)2SO4) precipitation are useful protocols for 
the partial purification of soluble proteins. pH precipitation relies on the fact that each 
protein has their own isoelectric point (pI) and is least soluble at this pI i.e. protein-
protein interactions become greater as a result of the electrostatic forces of the 
molecules being at their minimum and less water interacting with these proteins. These 
conditions are favourable for aggregation of proteins and possibly precipitation 
(Pelegrine and Gasparetto, 2005). Therefore, altering the pH conditions of crude extract 
from infiltrated and harvested leaf material may precipitate the protein of interest at one 
of the pH conditions tested. Contrastingly, altering the pH conditions of crude extract 
may precipitate out a majority of the other plant proteins at one of the pH conditions 
tested and leave the protein of interest in the supernatant. 
The method of ammonium sulphate precipitation is a convenient first step for separation 
of recombinant proteins of interest from other proteins in crude homogenate due to its 
low cost and selectivity benefits compared to other separation methods like ion-
exchange and gel filtration chromatographies (King, 1972). Ammonium sulphate 
precipitation makes use of the fact that increasing ionic strength reduces the solubility 
of soluble proteins in a process called ‘salting-out’. Thus, based on a protein’s solubility 
in the presence of varying salt ((NH4)2SO4) concentrations, the salting-out process can 
be used to separate proteins for partial purification (Duong-Ly and Gabelli, 2014). 
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(NH4)2SO4 is the salt of choice for initial separation of crude extracts since it yields 
precipitated proteins that are both denatured and concentrated in a small volume. 
However, contaminant proteins may be co-precipitated with the protein of interest. As 
such, if very pure preparations are needed, a further precipitation step, like ion-exchange 
chromatography, may be needed thereafter (Grodzki and Berenstein, 2010).  
The purification strategies used and described in this chapter include Ni-NTA affinity 
chromatography, pH precipitation, and ammonium sulphate precipitation. In addition, 
the exposure of the 6xHis-tag fused to the recombinant protein of interest was 
investigated to determine if a Ni-resin purification strategy would be effective. 
Thereafter, partial purification of CHIKV E2ΔTM-HIS proteins was investigated using pH 
and ammonium sulphate purification strategies. In addition, the presence of plant-
protein contaminants, like recombinant calreticulin (CRT) and RuBisCo, were investigated 
for in the ammonium sulphate fractions that precipitated CHIKV E2ΔTM-HIS to 
determine whether they co-purified with CHIKV E2ΔTM-HIS.  
 
3.2 Materials and Methods 
3.2.1 Nickel-Resin Purification  
Fifteen tobacco plants were co-infiltrated, as described in section 2.2.7, and soluble 
protein was extracted from harvested leaves, as described in section 2.2.8. Variable 
buffer reagents, buffer pH, imidazole concentrations, nickel resin volumes added, and 
binding times were tested for subsequent purification attempts. Despite the variable 
conditions mentioned above, the small- and large-scale methodology remained the 
same. A summary of these variable conditions can be found in Table 3.1.  
All steps were performed at room temperature and centrifugation done at 5000 x g for 
30 seconds. Variable volumes of HIS-Select® Nickel Affinity Gel (Sigma-Aldrich) were 
added to a 1.5 mL Eppendorf reaction tube and centrifuged and the supernatant 
subsequently discarded. Two hundred microlitres of equilibration buffer (components 
mentioned in Table 3.1) was added, mixed with the Ni-NTA and subsequently 
centrifuged. The supernatant was discarded and 100 µL of crude extract from harvested 
leaves was added to the equilibrated resin, mixed and incubated to allow proteins to bind 
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for variable amounts of time. The mixture was centrifuged and the supernatant stored 
and labelled “S1”. Thereafter, the mixture was washed with 500 µL of wash buffer 
(components mentioned in Table 3.1), mixed for 10 seconds and centrifuged. The 
supernatant was stored and labelled “S2”. The wash was repeated once more to obtain 
“S3”. Following this, 50 µL of elution buffer (components mentioned in Table 3.1) was 
added to the mixture, mixed well and centrifuged and the supernatant stored and 
labelled “E1”. This was repeated twice more, and the supernatants of each step were 
collected and labelled “E2” and “E3”. All fractions were denatured and analysed by SDS-
PAGE and Coomassie staining as described in section 2.2.5.  
When performed under denaturing conditions, 1 x PBS supplemented with 8M urea was 
used to extract recombinant proteins from harvested leaves. Likewise, the equilibration, 
wash and elution buffers used were supplemented with 8M urea. The elution buffer also 
lacked imidazole.  
 
3.2.2 Denaturing vs. Non-Denaturing Polyacrylamide Gels 
To investigate whether the 6xHis-tag is sufficiently exposed on the native conformation 
of the CHIKV E2ΔTM-HIS protein, the recombinant proteins were resolved by non-
denaturing PAGE and in parallel, for comparison, by denaturing PAGE.  
In order to maintain the native conformation of the CHIKV E2ΔTM-HIS proteins, the non-
denaturing polyacrylamide gel was made without 10% sodium dodecyl sulphate (SDS), 
to prevent irreversible linearization of the recombinant proteins. Additionally, the 5 x 
sample application buffer (SAB) used lacked β-mercaptoethanol, in order to retain 
disulphide bonds as well as SDS, and the samples were not heat denatured. In contrast, 
denaturing gels (SDS-PAGE) and treatment of CHIKV E2ΔTM-HIS proteins were carried 
out as described in section 2.2.5.   
The non-denaturing and denaturing gels were transferred onto the same sheet of 
nitrocellulose membrane adjacent to each other and screened by Western blotting, as 




3.2.3 pH Precipitation  
Crude extract was extracted from harvested leaves, as described in section 2.2.8, in a 1 
x PBS, pH 7.4 buffer. The pH of the crude extract was subsequently decreased to reach 
pH levels of 6.0, 5.5, 5.0, 4.5, 4.0 and 3.5 and 1 mL of sample from each pH level was 
transferred to Eppendorf reaction tubes. The samples were centrifuged at 13 000 rpm 
for 5 mins and the supernatants transferred to new reaction tubes. The pellets were 
resuspended in 100 µL of 1 x PBS, pH 7.4 to resolubilise any proteins that pelleted at the 
respective pH levels. The respective supernatants and pellets were denatured and 
analysed by SDS-PAGE and Coomassie staining, as described in section 2.2.5. Since 
samples were taken from the same crude extract at different pH levels, equal total 
soluble protein was compared between samples.  
 
3.3.4 Ammonium Sulphate Precipitation  
Proteins previously extracted, as described in 2.2.8, were fractionated by ammonium 
sulphate precipitation by the addition of solid (NH4)2SO4 to achieve 80% saturation. Each 
saturation step was done in 10% increments. The amount of (NH4)2SO4 to be added to 
increase saturation by 10% was calculated using an online ammonium sulphate 
calculator (http://www.encorbio.com/protocols/AM-SO4.htm). 
Initially, to achieve 10% saturation, solid (NH4)2SO4 was slowly added to freshly extracted 
proteins and left to equilibrate for 1 hr. This was done with constant stirring at 4 oC. Once 
equilibrated, the fraction was centrifuged at 10 000 x g for 15 min at 4 oC. The pellet was 
resuspended in 1.5 mL of 1 x PBS, pH 7.4, and stored at 4 oC for later dialysis of all 
resuspended samples. The calculated amount of solid (NH4)2SO4 was slowly added to the 
supernatant at 4 oC with constant stirring to perform the subsequent 20% saturation step 
in the precipitation and the above process repeated. This was repeated for the 30%, 40%, 
50%, 60%, 70%, and 80% saturation intervals.  
Each sample of resuspended pellet was dialysed to remove the (NH4)2SO4 for subsequent 
analysis of samples. Samples were dialysed O/N using tubing with a 10 kDa molecular-
weight cut-off (Thermo Fisher Scientific) in 1 x PBS, pH 7.4 at 4 oC with constant stirring. 
Dialysed pellet resuspensions were denatured and analysed by SDS-PAGE, as in section 
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2.2.5, and probed using Western blotting, as in section 2.2.6. Samples from the dialysed 
ammonium sulphate fractions in which CHIKV E2ΔTM-HIS were precipitated were also 
screened for the presence of CRT (as recombinant CRT was co-expressed with CHIKV 
E2ΔTM-HIS) to investigate whether CRT co-purified with CHIKV E2ΔTM-HIS by probing 
samples with anti-CRT antibodies (abcam, Cambridge, United Kingdom).  
 
3.3.5 Assessment of CHIKV E2ΔTM-HIS Purification Yields 
To quantify and compare the purification yield of CHIKV E2ΔTM-HIS in the respective 
samples obtained from the purification strategies investigated, the intensities of the ~49 
kDa bands in Western blots and Coomassie stains were observed. 
With regards to Table 3.1, the intensities of the bands observed in the wash (S) and 
elution (E) samples are represented by a ‘+’, where more ‘+’ indicate  higher intensities 
of the ~49 kDa band that represents the purification yield of CHIKV E2ΔTM-HIS in that 
sample (‘+’ indicates the band is just visible and ‘+++++’ indicates the band is at its highest 
intensity i.e. dark blue or dark purple in the Coomassies and Western blots, respectively). 
In contrast, a ‘-‘ indicates the lack of a ~ 49 kDa band i.e. an undetectable/no yield of 
CHIKV E2ΔTM-HIS obtained in the sample.  
 
3.3 Results 
3.3.1 Nickel-Resin Purification   
A one-step purification strategy was attempted to purify recombinant CHIKV E2ΔTM-HIS 
proteins using Ni-NTA affinity chromatography, under different buffer reagent, buffer 
pH, imidazole concentration, nickel resin volume added, and binding time conditions, to 
optimise the purification strategy. Table 3.1 summarises the Coomassie staining results 
of the ~49 kDa band intensities of CHIKV E2ΔTM-HIS in the wash (S) and elution (E) 
fractions observed.  
An in-house methodology using the protein extraction buffer (section 2.2.4 – 1 x PBS, pH 
7.4) as the protocol’s equilibration, wash and elution (supplemented with 250 mM 
imidazole) buffers was investigated. This methodology washed out the majority of the 
recombinant proteins in washes S1 - S3 with minimal protein elution (E1)(#1). The same 
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result was seen when the Ni-resin volume was increased (#2). Neither scaling up the 
methodology and increasing the salt and imidazole concentration, nor increasing the 
binding time, successfully eluted recombinant proteins (#3). When using the 
manufacturer-recommended buffers, the same result is seen (#4) even when increasing 
the binding time (#5). In addition, purification under denaturing conditions was 
unsuccessful (#6) including when the elution buffer pH was lowered from pH 5.5 to pH 
4.5 (#7). Since almost all the recombinant proteins are washed out during the 
equilibration wash, there seems to be no binding of the CHIKV E2ΔTM-HIS to the Ni-resin 




















Table 3.1: Ni-NTA affinity chromatography conditions and results. EqB, equilibration buffer; 
WB, wash buffer; ElB, elution buffer. S1, equilibration wash; S2 - S3, wash 2 - 3; E1 - E3, elution 1 
– 3. +, CHIKV E2ΔTM-HIS protein present in sample. Multiple ‘+’ indicate higher CHIKV E2ΔTM-
















Table 3.1 continued: Ni-NTA affinity chromatography conditions and results. EqB, equilibration 
buffer; WB, wash buffer; ElB, elution buffer. S1, equilibration wash; S2 - S3, wash 2 - 3; E1 - E3, 
elution 1 – 3. +, CHIKV E2ΔTM-HIS protein present in sample. Multiple ‘+’ indicate higher CHIKV 
E2ΔTM-HIS proteins present; -, protein absent in sample. 
 
 
3.3.2 Comparison of CHIKV E2ΔTM-HIS Resolved by Denaturing and Non-
Denaturing Gel 
The binding of anti-6xHis antibodies to denatured and non-denatured CHIKV E2ΔTM-HIS 
proteins was investigated by probing anti-6xHis antibodies to CHIKV E2ΔTM-HIS proteins 
resolved by denaturing and non-denaturing polyacrylamide gels, respectively (Fig. 3.1) 
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A dark purple band (~ 49 kDa) corresponding to CHIKV E2ΔTM-HIS was visualised on the 
denaturing blot (Den) whereas a much fainter one was visualised on the non-denaturing 
blot (ND).  This provided evidence that the 6xHis-tag on CHIKV E2ΔTM-HIS was not 
exposed and therefore explained the lack of CHIKV E2ΔTM-HIS purification using Ni-NTA 
affinity chromatography.   Consequently, other purification protocols were investigated.  
 
 
Figure 3.1: Western blot screening of CHIKV E2ΔTM-HIS proteins in their native conformation. 
A comparison of anti-6xHis antibody probing ability to denatured and non-denatured variants of 
the recombinant CHIKV E2ΔTM-HIS protein. M, MW marker; Den, denatured CHIKV E2ΔTM-HIS 
resolved by SDS-PAGE; -ve, protein extract from leaves infiltrated with empty pTRAkc-ERH; ND, 
non-denatured CHIKV E2ΔTM-HIS variant resolved by native-PAGE; red arrow; expected size of 
CHIKV E2ΔTM-HIS.  
 
3.3.3 pH Precipitation  
To investigate if pH precipitation can either partially or fully purify CHIKV E2ΔTM-HIS 
proteins from the remaining plant proteins, pellet and supernatant samples of crude 
extracts, harvested from infiltrated leaves, at different pH levels were screened for CHIKV 
E2ΔTM-HIS proteins. The supernatants and pellets of the pH precipitation samples were 
visualised by Coomassie staining (Fig. 3.2). 
Compared to the unprocessed crude extract (C), none of the pH conditions investigated 
allowed for sufficient CHIKV E2ΔTM-HIS purification as other plant proteins were present 
in all samples containing CHIKV E2ΔTM-HIS, evidenced by the presence of multiple bands 
in all the samples tested. CHIKV E2ΔTM-HIS was present in all samples except for in the 
supernatants of the pH 5.5 and pH 3.5 samples and the pellet of the pH 5.0 sample. It 
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was evident that higher levels of CHIKV E2ΔTM-HIS can be found in the opposite samples 
to those mentioned above i.e. the pellets of the pH 5.5 and pH 3.5 samples and the 
supernatant of the pH 5.0 sample. However, while this is desirable, there were still other 
proteins present in the samples screened. In addition, RuBisCo and recombinant CRT co-
purified with CHIKV E2ΔTM-HIS.    
 
 
Figure 3.2: Coomassie staining of pH precipitated crude extract. Supernatant and pellet 
samples of crude extract that have undergone pH precipitation between a pH range of 6.0 and 
3.5. M, MW marker; S, supernatant; P, pellet; C, unprocessed crude extract; red arrow; expected 
size of CHIKV E2ΔTM-HIS.  
 
 
3.3.4 Ammonium Sulphate Precipitation 
In order to purify CHIKV E2ΔTM-HIS, ammonium sulphate precipitation was performed 
on crude extracts from harvested leaves co-infiltrated with CHIKV E2ΔTM-HIS and CRT 
(Fig. 3.3A).  
Western blotting of both the 0 -10% and 80+% ammonium sulphate fractions indicated 
undetectable levels of CHIKV E2ΔTM-HIS proteins. Fractions 30-40%, 40-50% and 50-60% 
ammonium sulphate precipitated the most CHIKV E2ΔTM-HIS protein and fractions 10-
20%, 20-30%, 60-70% and 70-80% ammonium sulphate precipitated lower but 
detectable amounts of CHIKV E2ΔTM-HIS protein.  
Since the major plant contaminant RuBisCo precipitates at approximately 40% (Delgado 
et al., 1995, Uemura et al., 1996), only recombinant CRT was screened to identify if CRT 
co-purified with CHIKV E2ΔTM-HIS in samples 30-40%, 40-50%, and 50-60% ammonium 
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sulphate (Fig. 3.3B). CRT co-precipitated with CHIKV E2ΔTM-HIS in all samples screened 
as evidenced by the presence of the intense ~49 kDa bands. 
 
 
Figure 3.3: Western blot screening of ammonium sulphate-precipitation samples. Anti-6xHis 
and anti-CRT probing of resolved crude extract saturated from 0 – 80+% and 30 – 60% with 
ammonium sulphate for CHIKV E2ΔTM-HIS (A) and CRT (B) screening, respectively. M, MW 
marker; red arrow, expected size of recombinant protein of interest; -ve, no-CRT negative 
control; +ve, positive control generated by anti-CRT probing of crude extract harvested from 
leaves infiltrated with pEAQ-HT CRT.  
 
3.4 Discussion 
Industrial processes for the downstream processing of microbial- and mammalian cell-
produced recombinant proteins are a well-established practice; however, DSP remains 
the majority of the overall cost (Schillberg et al., 2019). While plant-expression systems 
potentially offer a cheaper alternative (due to low-cost upstream cultivation) to 
recombinant protein production (Tschofen et al., 2016), whole plant-produced 
recombinant proteins are extracted simultaneously with a large quantity of insoluble 
proteins of the plant matrix and other soluble plant host proteins. This requires the 
elimination of large quantities of contaminants during DSP and this has the potential to 
complicate purification of the protein of interest and further increase DSP costs 
(Schillberg et al., 2019). Cheap and efficient downstream processing protocols are critical 
for the development of cost-effective biopharmaceuticals in plants. A one-step 
purification strategy is favoured over partial purification since partial purification takes 
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multiple steps to eventually fully purify the recombinant protein of interest and, as a 
result, increases the costs and labours of DSP.  
Previous studies have shown the efficiency of using Ni-NTA chromatography to purify 
recombinant 6xHIS-tagged CHIKV E2 glycoproteins in insect (Cho et al., 2008, Bagno et 
al., 2020), E. coli (Verma et al., 2016, Bagno et al., 2020) and mammalian cells (Bagno et 
al., 2020). These studies present further evidence for how the 6xHis-tag and Ni-NTA 
chromatography provide a universal purification system of recombinant antibodies: if 
recombinant proteins are insoluble, located in inclusion bodies and/or have a tertiary 
structure such that the 6xHis-tag is hidden within, proteins can be extracted under 
denaturing conditions and subsequently purified successfully. Another strategy used that 
has the potential to bypass denaturing conditions is the movement of the 6xHis-tag to 
the opposite terminus of the protein (Crowe et al., 1994). An attempt at one-step 
purification using Ni-NTA affinity chromatography was unsuccessful under multiple 
conditions. Most of the CHIKV E2ΔTM-HIS protein washed out in equilibration wash S1 
and the rest in washes S2 – S3, with zero to minimal elution of CHIKV E2ΔTM-HIS proteins 
(Table 3.1). This indicates a lack of protein binding to the Ni-resin by way of the fused 
6xHis-tag. It is possible that nickel affinity purification was unsuccessful due to the 6xhis-
tag being insufficiently exposed on the native CHIKV E2ΔTM-HIS protein to bind to 
immobilised Ni-ions of the Ni-affinity resin. In rare cases, the 6xHis-tag becomes hidden 
by the tertiary structure of the protein (Crowe et al., 1994). It is known that the stability 
of the interaction of the 6xHis-tag to the immobilised Ni-resin is dependent on how 
accessible the tag is on the protein of interest (Block et al., 2009). To investigate this, 
CHIKV E2ΔTM-HIS proteins were resolved by non-denaturing as well as denaturing 
polyacrylamide gels and probed by western blotting using anti-6xHis antibodies to 
compare anti-6xHis antibody binding by assessing the intensity of the CHIKV E2ΔTM-HIS 
protein bands (Fig. 3.1). Analysis of CHIKV E2ΔTM-HIS in its native conformation by 
native-PAGE showed that the 6xHis-tag is not exposed as anti-6xHis antibodies were 
unable to bind the 6xHis-tag when CHIKV E2ΔTM-HIS is in its native conformation (Fig. 
3.1). Consequently, the problems with the binding of CHIKV E2ΔTM-HIS to the 
immobilised Ni-resin was credited to the unexposed 6xHis-tag. While denaturing 
conditions were used to remedy these problems, they were not satisfactory. It may be 
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worth attempting to purify the recombinant CHIKV E2ΔTM protein with the 6xHis-tag on 
the opposite terminus as this may bypass the need to alter conditions and may even 
allow for purification of the recombinant protein under non-denaturing conditions 
(Crowe et al., 1994). While this may have shown promising results, the time-constraints 
present at this stage of the study did not permit additional cloning, expression time-trials 
and further purification experimentation. Thus, alternative purification strategies were 
tested.  
Since the pI of a protein of interest can be utilised to precipitate proteins at a pH level 
closest to that of the protein’s pI (Pelegrine and Gasparetto, 2005), a pH precipitation 
protocol was performed on crude extract. This investigated whether CHIKV E2ΔTM-HIS, 
or a large portion of the other plant proteins (the large subunit of RuBisCo and CRT 
especially), would precipitate under different pH conditions in order to either fully or 
partially purify CHIKV E2ΔTM-HIS (Fig. 3.2). None of the pH conditions were able to purify 
CHIKV E2ΔTM-HIS fully or sufficiently enough for partial purification. Furthermore, the 
large subunit of RuBisCo and CRT contaminants were present in all samples that 
contained CHIKV E2ΔTM-HIS. Thus, pH purification is not an efficient strategy for CHIKV 
E2ΔTM-HIS purification.  
Ammonium sulphate precipitation has remained the most widely used precipitation 
method. Ammonium sulphate is stabilising to the structure of proteins, very soluble, 
relatively cheap and has readily available pure material (Burgess, 2009). Since 
ammonium sulphate precipitation is a tried and tested purification strategy, crude 
extract underwent this protocol to investigate if CHIKV E2ΔTM-HIS proteins can be 
efficiently purified. Fractions were screened for CHIKV E2ΔTM-HIS and possible protein 
contaminants, like recombinant CRT and RuBisCo, in samples where CHIKV E2ΔTM-HIS 
precipitated to investigate the purity of the fractions (Fig. 3.3). While CHIKV E2ΔTM-HIS 
precipitated in a large saturation range (10 – 80%), fractions 30 – 60% precipitated most 
of the protein with no detectable protein precipitation seen in fractions 0-10% and 80+% 
ammonium sulphate. In studies where RuBisCo was purified by ammonium sulphate 
precipitation (Delgado et al., 1995, Uemura et al., 1996), and in-house ammonium 
sulphate precipitation results, RuBisCo precipitates at approximately 40% ammonium 
sulphate i.e. one of the saturation levels where CHIKV E2ΔTM-HIS more predominantly 
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precipitated. However, CHIKV E2ΔTM-HIS was still predominantly precipitated in 
fractions higher than 40% ammonium sulphate (40 – 70%). Therefore, only the presence 
of recombinant CRT was screened for since literature (Delgado et al., 1995, Uemura et 
al., 1996) provided RuBisCo’s ammonium sulphate precipitation results. Screening of 
recombinant CRT in fractions 30 – 80% indicated that the highest levels of CRT co-purified 
in the fractions where CHIKV E2ΔTM-HIS most predominantly precipitated. Therefore, 
while ammonium sulphate is able to largely precipitate CHIKV E2ΔTM-HIS between 30 – 
60% ammonium sulphate, RuBisCo and CRT proteins contaminate these fractions.  
While CHIKV E2ΔTM-HIS was partially purified by ammonium sulphate precipitation, 
another purification step is needed thereafter to remove RuBisCo and CRT contaminants. 
Whether CRT and plant-protein contaminants will influence background in a 
downstream diagnostic assay is unknown; however, it is ideal that they be removed 
during the purification process. It would be worth investigating a second purification step 
by means of ion-exchange chromatography. This was not performed due to time 
constraints. In addition, it is worth investigating the exposure of a 6xHis-tag when fused 
to the C-terminus of CHIKV E2ΔTM, as opposed to the N-terminus in this study, as this 
conformation may expose the 6xHis-tag and allow for one-step purification by Ni-NTA 
chromatography. If the elution is still not pure enough, ammonium sulphate precipitation 
is often performed before Ni-NTA chromatography to remove the majority of the other 
plant protein contaminants. Otherwise, optimising an Ni-NTA chromatography 
technique under denaturing conditions of CHIKV E2ΔTM-HIS to expose the 6xHis-tag 










Chapter 4: Conclusion 
In this study, two variants of the CHIKV E2 envelope glycoprotein were expressed in 
Nicotiana benthamiana plants for the development of a diagnostic reagent for the 
detection of CHIKV antibodies. The CHIKV E2 protein is an appropriate candidate for a 
CHIKV diagnostic reagent owing to its conservation and the fact that it is a major target 
for neutralizing antibodies against CHIKV during early infection.  
The two synthesised CHIKV E2 gene variants were successfully cloned into pTRAkc-ERH 
plant expression vector. However, cloning of the same gene variants into pEAQ-HT plant 
expression vector was unsuccessful, despite the generation of two different cloning 
strategies. This may have been due to the size of the pEAQ-HT vector and the CHIKV E2 
variant-gene inserts that were to be ligated into it. Likewise, the size of the resulting 
expression construct may have been too big to successfully transform into bacteria, as 
the bigger the construct to be transformed, the less likely transformation will be 
successful. Additionally, the pTRAkc-ERH expression constructs were successfully 
transformed into A. tumefaciens – as the pTRAkc-ERH constructs were smaller than the 
pEAQ-HT constructs - and subsequently expressed in Nicotiana plants. 
The expression of both recombinant CHIKV E2 glycoprotein variants in Nicotiana 
benthamiana plants was successful. Previous work on CHIKV E2 and CHIKV E2ΔTM in 
insect cells has shown similar results: the transmembrane-deficient variant expressed 
higher levels of protein than the full-length variant. It is known that transmembrane 
proteins are often difficult to express in heterologous hosts and are often toxic to the 
host cell. Elimination of the transmembrane domain of proteins has been shown to allow 
or improve expression of the truncated protein. This may be the reason for the 
transmembrane-deficient variant of the CHIKV E2 glycoprotein expressing at higher 
levels than the full-length CHIKV E2 glycoprotein.  
Although the CHIKV E2 protein variants produced in plants were detectable, yields were 
still not very high in comparison with the levels of many other recombinant proteins 
produced in plants.  Since one of the most desirable outcomes of utilising plant-produced 
proteins is the generation of cost-effective reagents, it would be prudent to increase 
expression levels of CHIKV E2 variants.  There are several approaches that one could 
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employ to do this. We showed with this work, that the co-expression of the chaperone 
protein CRT with CHIKV E2ΔTM-HIS increased its production. Chaperone proteins are 
responsible for the correct folding, during or after synthesis, of proteins and recombinant 
NSs can be used as a tool to suppress the deleterious effects of RNA silencing of 
exogenous expression of recombinant proteins and improve their expression. In 
addition, the recombinant chaperones are theorised to bridge the gap between the 
inherent differences in endogenous chaperone machinery between the plant and natural 
mammalian cell hosts - where viral glycoproteins are naturally produced - in addition to 
a potential bottleneck in the plant folding machinery to produce exogenous viral 
glycoproteins. The improved expression seen for the CHIKV E2-HIS variants when co-
expressed with these proteins (co-expression of CHIKV E2ΔTM-HIS and CRT especially) 
may be credited to these reasons. This provided further evidence for the benefits of 
reducing the limitations of plant-expression technology by means of further optimisation 
strategies. Selection, optimisation, and extraction of the best expressed CHIKV E2 variant 
was successful and the conditions were scaled up. Co-expression of CHIKV E2ΔTM-HIS 
and CRT resulted in the highest yield of recombinant CHIKV E2ΔTM-HIS proteins when 
infiltrated plant leaves were harvested 3 days post-infiltration (dpi) and total soluble 
proteins extracted in a 1 x PBS, pH 7.4 buffer. While co-expression of the CHIKV E2 
protein variants with NSs and CNX did improve its expression on certain dpi, the 
expression levels were still not sufficient to achieve the yields needed for a diagnostic 
reagent.   
It is possible that the low levels of expression may be due to degradation of CHIKV E2-
HIS protein variants as a result of underglycosylation. Co-expressing the CHIKV E2 
glycoprotein variants with a recombinant oligosaccharyltransferase from Leishmania 
major would have been worth investigating as this has been shown to substantially 
increase N-glycosylation occupancy on N-glycosylation sites of other recombinant 
glycoproteins before. This is vital since glycosylation facilitates protein folding, stability, 
and the modulation of protein-protein interactions. Co-expression of CHIKV E2-HIS 
variants in the glycol-engineered ΔXT/FT N. benthamiana line – a plant line that lacks 
plant-specific β-1,2-linked xylose and core α-1,3-linked fucose - with a recombinant 
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oligosaccharyltransferase from Leishmania major may have had similar if not better 
results.  
Fusing a 6xHis-tag onto the C-terminus of each variant provided a suitable detection and 
verification strategy using anti-HIS antibodies in lieu of anti-CHIKV E2 antibodies. While 
anti-CHIKV E2 antibodies are ideal, their availability during the research project were 
limited and expensive. Additionally, the 6xHis-tag is a cheaper alternative that 
contributes to the cost-effective advantage of biopharmaceutical development in plants. 
The 6xHis-tag is also a widely-used technology for detection and purification of 
recombinant proteins. However, while detection of recombinant CHIKV E2 proteins was 
successful using the 6xHis-tag, purification of plant-produced CHIKV E2ΔTM-HIS proteins 
by Ni-NTA affinity chromatography proved troublesome owing to the unexposed 6xHis-
tag hidden within the recombinant proteins tertiary structure. This is not ideal since, 
while plant-expression systems boast lower upstream costs compared to the more 
traditional expression systems, downstream-processing remains the largest contributor 
to overall development costs. Therefore, since one-step purification of the CHIKV 
E2ΔTM-HIS protein by Ni-NTA affinity chromatography failed, additional cost-raising 
steps need to be included in the purification of the recombinant proteins.  
Purification of CHIKV E2ΔTM-HIS proteins by pH precipitation was unable to separate 
CHIKV E2ΔTM-HIS proteins from other soluble plant proteins. This protocol only relies on 
the difference of pI between the soluble proteins and is not as specific as Ni-NTA 
chromatography to bind and elute only the proteins containing a 6xHis-tag. Ammonium 
sulphate precipitation was able to best precipitate CHIKV E2ΔTM-HIS proteins between 
30-60% ammonium sulphate. However, RuBisCo and large amounts of recombinant CRT 
contaminated these samples in the fractions below 40% ammonium sulphate and 30-
60% ammonium sulphate, respectively. Recombinant CRT proteins may be precipitating 
with the CHIKV E2ΔTM-HIS proteins as their solubility in the presence of varying salt 
((NH4)2SO4) concentrations may be similar. This would require a further purification step 
to separate CHIKV E2ΔTM-HIS proteins from the remaining plant contaminants. Future 
research should be done on fully purifying CHIKV E2ΔTM-HIS proteins in the dialysed 30-
60% ammonium sulphate fractions by ion-exchange chromatography. In addition, it 
should be investigated and compared whether fusing the 6xHis-tag onto the C-terminus, 
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as well as or in lieu of the N-terminal 6xHis-tag, of recombinant CHIKV E2ΔTM will expose 
the tag(s) sufficiently and allow for the one-step purification of CHIKV E2ΔTM-HIS by Ni-
NTA affinity chromatography.   
In conclusion, this research investigates the feasibility and functionality of using 
recombinant plant-produced CHIKV E2 glycoprotein variants to develop a cheap and 
efficacious diagnostic assay for the rapid detection of CHIKV infection. This study further 
corroborates the merits of using a tobacco plant-expression technology for the 
development of a cost-effective, efficacious biopharmaceuticals. In addition, it highlights 
the limitations of the respective stages of the technology and, in some cases, how to 
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Figure A1: Consensus sequence of full-length CHIKV E2. Three South African CHIKV isolates (GenBank: 
HM045792.1, Vereeniging, Gauteng province; HM045795.1, SAH2123 strain; HM045805.1, CHIKV AR 
18211 1976) were used to generate a consensus sequence. Highlighted sequence represents the 
transmembrane domain that is removed to generate the CHIKV E2ΔTM variant. 
